If you're seeing this message, it means we're having trouble loading external resources on our website. Show
If you're behind a web filter, please make sure that the domains *.kastatic.org and *.kasandbox.org are unblocked. Journal Article Brad Spellberg, 1 Department of Internal Medicine, Harbor-University of California Los Angeles Medical Center , Torrance, California Reprints or correspondence: Dr. Brad Spellberg, Dept. of Medicine, Harbor-UCLA Medical Center, 1000 West Carson St., Torrance, CA 90509 ( ). Search for other works by this author on: John E. Edwards, Jr.1 Department of Internal Medicine, Harbor-University of California Los Angeles Medical Center , Torrance, California 2 Division of Infectious Diseases, Harbor-University of California Los Angeles Medical Center , Torrance, California Search for other works by this author on: Financial support: National Institutes of Health / National Insititute of Allergy and Infectious Diseases (grants RO1 AI19990 and PO1 AI37194), University of Alabama Clinical Trials of Antifungal Therapies, and Bristol Meyers Squibb Award. Author Notes Revision received: 02 August 2000 Published: 01 January 2001
Close Navbar Search Filter Microsite Search Term Search AbstractT helper type 1 (Th2) lymphocytes secrete secrete interleukin (IL)-2, interferon-γ, and lymphotoxin-α and stimulate type 1 immunity, which is characterized by intense phagocytic activity. Conversely, Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 and stimulate type 2 immunity, which is characterized by high antibody titers. Type 1 and type 2 immunity are not strictly synonymous with cell-mediated and humoral immunity, because Th2 cells also stimulate moderate levels of antibody production, whereas Th2 cells actively suppress phagocytosis. For most infections, save those caused by large eukaryotic pathogens, type 1 immunity is protective, whereas type 2 responses assist with the resolution of cell-mediated inflammation. Severe systemic stress, immunosuppression, or overwhelming microbial inoculation causes the immune system to mount a type 2 response to an infection normally controlled by type 1 immunity. In such cases, administration of antimicrobial chemotherapy and exogenous cytokines restores systemic balance, which allows successful immune responses to clear the infection. Historical BackgroundAt the turn of the 20th century, the new science of immunology was in the throes of a fundamental debate: were phagocytic cells the keys to protection against infection, as proposed by Metchnikoff [ 1 ], or were humoral antibodies the true protective factors, as forwarded by Koch's students, von Behring and Ehrlich [ 2 ]? Although the humoralists at first carried the day, the joint awarding of the 1908 Nobel Prize in Medicine to the opponents, Metchnikoff and Ehrlich, was prophetic. By the end of the century, the opposing theories created by these two fathers of immunology would be unified in one paradigm of host defense against infection: type 1/type 2 immunity. The terms type 1 and type 2 immunity bear no relation to types 1–4 of hypersensitivity reactions described by Gell and Coombs [ 2a ]. Rather, the birth of the type 1/type 2 immunity paradigm can be traced to landmark articles by Parish in the early 1970s [ 3–5 ]. Building on studies of immune regulation by Sercarz and Coonz [ 6 ], Dresser [ 7 , 8 ], and Mitchison [ 9 ], Parish described a striking inverse correlation between the degree to which a given dose of antigen elicited antibody production or delayed type hypersensitivity (DTH; figure 1 ). His results, confirmed by other investigators utilizing different experimental models [ 10–12 ], were the bedrock of what would become the type 1/type 2 hypothesis: the level of antibody elicited in an immune response is inversely proportional to the level of cell-mediated immunity. Figure 1  Murine humoral and cell-mediated immune (CMI) responses to a broad range of Salmonella flagellin doses are inversely related. Humoral response is quantified by antibody titer, whereas CMI response is quantified by the footpad-swelling reaction, a form of delayed-type hypersensitivity (figure reproduced with permission from [ 3 ]). Given the link between humoral and cell-mediated immunity, there was much interest in characterizing the regulation of these alternate forms of host defense. By the early 1980s the 2 major subsets of T lymphocytes had been described: T helper cells, which express the surface protein CD4, and T-cytotoxic cells, which express the CD8 marker ( figure 2 ). Whereas CD8 + T-cytotoxic lymphocytes were known to mediate lysis of autologous cells infected by intracellular pathogens, CD4 + T helper cells were known to induce B cell production of antibodies. Their stimulation of antibody responses made T helper cells the natural subjects of investigations into the common regulation of humoral and cell-mediated immunity. Figure 2 Antigen presentation to T-cytotoxic (CD8 + ) and T helper (CD4 + ) cells. In A , a host cell is (1) infected by an intracellular pathogen (a virus, in this example). (2) As progeny virions are produced, viral antigens are pumped into the endoplasmic reticulum, where they bind to class I major histocompatibility complex (MHC I) proteins. (3) Covalent interaction with the chaperone protein, β-2 microglobulin (β-2M) , allows surface expression of the MHC I polypeptide, which presents viral antigen bound to a groove at its tip. The CD8 protein on the T-cytotoxic cell binds to the MHC I molecule, stabilizing the interaction between the T-cell receptor (TCR) and the MHC I–antigen complex. (4) The result is activation of the T-cytotoxic cell, which then lyses the host cell to expose the intracellular virus. In B , a phagocyte (1) ingests extracellular microbes and degrades them in the phagolysosome. (2) Degraded microbial fragments are loaded onto class II MHC molecules in the phagolysosome, and the MHC II–antigen complexes are transported to the cell surface. (3) CD4 binds to MHC II, stabilizing the interaction between the TCR and the MHC II–antigen complex. (4) The result is activation of the T helper cell, which then autocrine-stimulates its own proliferation by secreting IL-2. It was in an effort to elucidate the role of T helper lymphocytes in induction of the DTH reaction that Mosmann et al. [ 13 ] first described the existence of subpopulations of CD4 cells known as T helper type 1 (Th2) and T helper type 2 (Th2) lymphocytes. By assaying cytokine production of CD4 + T helper cells from inbred mice, the investigators were able to divide the T cell clones into 2 phenotypes. Th2 cells produced IL-2, IFN-γ, and lymphotoxin (LT)-α. Conversely, Th2 cells produced IL-4 as well as other cytokines that had yet to be characterized. Both Th2 and Th2 cells provided help to B cells in antibody assays, but, as reported by Cher and Mosmann a year later, only Th2 cells, and not Th2 cells, could elicit DTH in mice [ 14 ]. TH1/TH2 Cell BiologyDefinitions. Th2 and Th2 cells are now known to exist in human beings as well as mice [ 15 , 16 ]. All T helper lymphocytes start out as naive Th0 cells, which, after being activated, are capable of “polarizing,” or differentiating, into either Th2 or Th2 effector cells [ 17 , 18 ]. Mature Th2 cells secrete IL-2, IFN-γ, and LT-α, and Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13 [ 19 , 20 ] (some investigators include IL-6, although this is controversial [ 21 , 22 ]). In humans this division is not as stringent as in inbred mice. For example, some human Th2 cells secrete IL-10 [ 23 ] and IL-13 [ 24 ]. In part because of such an overlap of cytokine secretion, the conventional definition of a Th2 or Th2 cell depends strictly on the secretion of IFN-γ or IL-4. Th2 cells secrete IFN-γ but do not secrete IL-4, whereas Th2 cells secrete IL-4 but not IFN-γ. T cells secreting neither IFN-γ nor IL-4 are neither Th2 nor Th2 cells. Some of these cells are naive Th0 lymphocytes that have never before been activated and thus have not acquired the ability to secrete a mature profile of cytokines. Aside from Th2 and Th2 cells, several other subtypes of T helper cells have been described ( table 1 ), and indeed the frequency of polarization to the Th2 or Th2 phenotype in vivo is controversial [ 30 , 31 ]. Like naive T cells, mature T cells secreting both IFN-γ and IL-4 are also known as Th0 cells, which can lead to some confusion. These latter Th0 cells are lymphocytes that did not polarize during maturation and thus took on attributes of both Th2 and Th2 cells [ 32 , 33 ]. Additional populations of CD4 + T helper lymphocytes called Th3 cells and T-regulatory 1 (Tr1) cells have been described. Th3 cells secrete transforming growth factor (TGF)-β and are thought to regulate mucosal immunity in mammals [ 34–37 ]. Tr1 cells, which appear to be similar to Th3 cells, secrete unusually high levels of IL-10 and also lower levels of TGF-β, and they have been implicated in general suppression of immunity [ 38 , 39 ]. Th3 and Tr1 cells are beyond the scope of this review, which will focus on Th2 and Th2 cells, the crucial cell types in defining the type 1/type 2 paradigm. Table 1 Subtypes of CD4 + T-helper (Th) cells and their characteristic cytokines and effects. Effects of Th2 and Th2 cells. Th2 cells are the principal regulators of type 1 immunity. The cytokine chiefly responsible for their proinflammatory effect is IFN-γ. IFN-γ stimulates phagocytosis [ 40 , 41 ], the oxidative burst [ 42 , 43 ], and intracellular killing of microbes [ 44–46 ]. IFN-γ also upregulates expression of class I [ 47 , 48 ] and class II major histocompatibility complex (MHC) molecules [ 49 , 50 ] on a variety of cells, thereby stimulating antigen presentation to T cells ( figure 2 ). Both IFN-γ and LT-α induce other cell types, including nonleukocytes such as endothelial cells [ 51 ], keratinocytes [ 52 ], and fibroblasts [ 53 , 54 ], to secrete proinflammatory cytokines, such as TNF and chemotactic cytokines called chemokines [ 55 ]. They also stimulate adhesion molecule expression on endothelial cells and induce endothelial cell retraction and vascular smooth-muscle relaxation. The result is accumulation of blood in dilated, leaky vessels, easing diapedesis of leukocytes into areas of danger and allowing recruitment of innate immune cells and opsonins into the interstitium. Thus Th2 cells cause rubor (redness), tumor (swelling), dolor (pain), and calor (warmth), the 4 cardinal signs of inflammation. Th2 cells, conversely, stimulate high titers of antibody production. In particular, IL-4, IL-10, and IL-13 activate B cell proliferation, antibody production, and class-switching [ 56–58 ]. In fact, class-switching from IgG to IgE cannot occur without the presence of IL-4 or IL-13 [ 59–61 ], making the production of IgE a perfect bioassay for the presence of Th2 cells in vivo. IL-5 is a potent hematopoietic cytokine that stimulates bone marrow production of eosinophils [ 62–64 ], as well as activation and chemotaxis of eosinophils [ 65 , 66 ] and basophils [ 67 , 68 ], whereas IL-9 is the equivalent hematopoietic and stimulatory factor for mast cells [ 69 , 70 ]. It is interesting that IL-4, IL-5, IL-9, and IL-13 have been strongly implicated in allergic and atopic reactions, as well as in causing the airway inflammation seen in asthma and reactive airway disease [ 71–78 ]. Unlike inflammation stimulated by type 1 cytokines, type 2–mediated inflammation is characterized by eosinophilic and basophilic tissue infiltration, as well as extensive mast cell degranulation, a process dependent on cross-linking of surface-bound IgE. In addition to their stimulatory effects, Th2 and Th2 cells cross-regulate one another. The IFN-γ secreted by Th2 cells directly suppresses IL-4 secretion and thus inhibits differentiation of naive Th0 cells into Th2 cells [ 79–81 ]. Conversely, IL-4 and IL-10 inhibit the secretion of IL-12 and IFN-γ, blocking the ability of Th0 cells to polarize into Th2 cells [ 82–84 ]. IL-10 is perhaps the most anti-inflammatory cytokine known [ 85 ]. It inhibits the secretion of proinflammatory cytokines [ 86 , 87 ]; suppresses phagocytosis [ 88 ], the oxidative burst [ 89 , 90 ], and intracellular killing [ 91 , 92 ]; and inhibits antigen presentation to T cells [ 93 , 94 ], causing T cell anergy [ 95 ]. Like IL-10, IL-4 and IL-13 also inhibit phagocytosis and intracellular killing [ 91 , 92 ], suppress inflammatory cytokine production [ 96 ], and may induce T cell anergy [ 97 ]. There are also differences in proliferation requirements between Th2 and Th2 cells. Naive T cells and Th2 cells absolutely require IL-2 for activation and proliferation [ 98 ]. However, Th2 cells are perfectly capable of proliferating without IL-2 if IL-4 [ 98 , 99 ] and/or IL-1 [ 100 , 101 ] is present, which is convenient for them since they secrete large quantities of IL-4. Therefore, in clinical situations where IL-2 is in limited supply (for example, in patients taking cyclosporine or FK-506 or high-dose glucocorticoids), only Th2 cells will be able to proliferate in response to antigenic exposure. TH1 AND TH2 RegulationFive Factors Inducing PolarizationFive factors regulate the polarization of newly activated naive T cells into mature Th2 or Th2 cells [ 19 , 102 ]: the local cytokine milieu; the presence of immunologically active hormones; the dose and route of antigen administration; the type of antigen-presenting cell stimulating the T cell; and the “strength of signal,” which is an ill-defined summation of the affinity of the T-cell receptor for the MHC-antigen complex, combined with the timing and density of receptor ligation. Of these 5 factors, the most important is the cytokine milieu surrounding the newly activated T cell. Cytokines. The key to polarization into the Th2 phenotype is IL-12 [ 103–106 ]. Conversely, IL-4 is the sine qua non for Th2 polarization [ 107–110 ]. Recent studies have indicated that the phenotype of a newly activated T cell is determined within 48–72 h after activation [ 110 , 111 ]. This correlates with the in vivo finding that T cells activated in lymph nodes do not polarize until they are exposed to specific cytokine milieus after traveling to peripheral effector sites, which occurs 2–3 days following activation [ 112 ]. Thus Th2 or Th2 polarization may not occur until an activated T cell arrives at the site of danger and samples the local cytokine milieu to determine if an inflammatory or antibody response is appropriate. T cells exposed to IL-12 during this time differentiate to become Th2 cells, and T cells exposed to IL-4 differentiate to become Th2 cells. When the immune system is “in doubt” about whether Th2 or Th2 cells should be generated, Th2 outcomes are favored. For instance, if both IL-12 and IL-4 are present at the time of T cell activation, the effect of the IL-4 dominates, and the T lymphocytes polarize to become Th2 effectors [ 103 , 104 , 113 ]. Whether or not established Th2 and Th2 clones can be made to reverse their phenotypes is controversial [ 113 , 114 ], but it is known that the responses of both Th2 and Th2 cells are reversible at the population level [ 115 , 116 ], which presents something of a conundrum. If individual T cell clones are nearly impossible to reverse, how can the response of an entire population of T cells be reversed? The answer is that even in highly polarized T cell populations, quiescent clones of the phenotype opposite to the dominant response can be found by fluorescence-activated cell-sorting (FACS) or limiting dilution analysis. That is, quiescent Th2 cells can be found in populations secreting large amounts of IL-4 and IL-10, and quiescent Th2 cells can be found in populations secreting IFN-γ and IL-2 [ 117–119 ]. Reversal of a population response involves inhibiting the dominant clones and allowing expansion of the quiescent clones by modulating the cytokine environment. Therefore, the nature of an immune response cannot be reliably determined from cytokine patterns of individual T cell clones, which may or may not be representative of the dominant population phenotype. Furthermore, B cells, phagocytes, and even nonleukocytes can secrete cytokines typical of a Th2 or Th2 cell (e.g., IFN-γ, IL-4, and IL-10). For these reasons, the terms “Th2 response” and “Th2 response,” which imply only measurement of responses by T helper cell clones, are insufficient. Instead, as originally proposed by Clerici and Shearer in the context of HIV [ 120 ], the terms “type 1 response” and “type 2 response” should be used to indicate a summation of the systemic response to a given infection (i.e., a type 1 response is characterized by high in vivo production of the Th2 cytokines IL-2, IFN-γ, and LT-α, without implying that these cytokines are exclusively being produced by T helper cells). Hormones. Glucocorticoids are powerful stimulators of type 2 outcomes and powerful inhibitors of type 1 outcomes, directly inducing IL-4 and IL-10 production from lymphocytes and antigen-presenting cells [ 121–123 ] while suppressing the secretion and effects of IFN-γ and IL-12 [ 124–127 ]. Furthermore, they suppress secretion of IL-2 [ 128 , 129 ], which inhibits activated Th2 cells from proliferating while allowing Th2 cells to expand. It is interesting that at high concentrations, glucocorticoids induce lympholysis [ 130 ] and inhibit all cytokine secretion, including type 2 cytokines [ 131 , 132 ]. In order to suppress lymphocyte proliferation and type 2 cytokine production in vitro, glucocorticoids must be present at at least 10 −7M concentrations [ 132–134 ]. Although direct comparison with in vivo serum concentrations is problematic, it has been estimated that serum glucocorticoid levels must reach ∼10 −6M to be clinically effective in reactive airways disease [ 135 ]. A study of patients receiving iv prednisolone indicated that a dose of 1 mg/kg markedly diminished serum T cell concentrations and ex vivo cytokine production, whereas a dose of 0.1 mg/kg mediated minimal changes in serum T cell counts and cytokine production [ 136 ]. Thus, at doses used clinically (∼40–60 mg of methylprednisolone per day), serum cortisol levels exceed those required to suppress type 2 cytokine secretion, a circumstance that probably explains the efficacy of steroid pulses in the treatment of reactive airways disease. Like glucocorticoids, estrogens and progestins have been shown to suppress type 1 immunity in favor of type 2 immunity. Both estrogens and progestins inhibit IL-12 and IFN-γ secretion from antigen-presenting cells and T cells, while stimulating IL-4, IL-10, and IL-13 secretion [ 137–139 ]. The persistence of the allogeneic fetus in its pregnant mother is perhaps the most compelling example of immunologic tolerance known. Placental secretion of estrogens, progestins, IL-4, and IL-10 [ 140 , 141 ], which produces type 2 responses to antigenic stimulation during pregnancy [ 142 ], is largely responsible for this peripheral tolerance. Aberrant regulation allowing type 1 immunity to occur during pregnancy leads to abnormal labor [ 143 , 144 ] or maternal rejection of fetal tissues, causing abortion [ 145–147 ]. Conversely, the testosterone derivative dehydroepiandrosterone (DHEA) has been shown to potentiate IL-2 secretion as well as the establishment of Th2 clones [ 148–150 ]. Therefore, male hormones favor cell-mediated immune responses, whereas female hormones favor humoral immunity. Indeed, in a direct comparison of coxsackievirus infection in male and female mice under identical experimental conditions, male mice mounted type 1 responses to the virus but female mice mounted type 2 responses [ 151 ]. Perhaps the most important hormones regulating type 1 and type 2 outcomes are the catecholamines. It has been known for 30 years that lymphocytes express catecholamine receptors [ 152 ]. Catecholamines inhibit type 1 cytokine production [ 153 ] and stimulate the transcription and secretion of type 2 cytokines from a variety of leukocytes [ 154–158 ]. Furthermore, the selective suppression of IL-2 production by catecholamines inhibits Th2 propagation, allowing selective Th2 proliferation [ 159 ]. β-2 Agonists are extremely potent bronchodilators, a characteristic explaining why they are acutely effective for symptomatic asthma. However, their effects on type 2 cytokines suggest that over the long term they might exacerbate the airway inflammation typical of asthma, which may explain why they must be combined with inhaled steroids to be effective as long-term suppressive therapy. Finally, other hormones have been shown to modulate type 1 and type 2 outcomes. Chief among these are human chorionic gonadotropin [ 160 ], prostaglandins (PGs, especially PGE) [ 161–164 ], and α-melanocyte-stimulating hormone [ 165 , 166 ], each of which has been shown to suppress type 1 cytokine responses while stimulating type 2 responses. Antigen dose. The effect of antigen dose on the polarization of naive cells to Th2 or Th2 cell types is poorly understood. The use of widely disparate experimental models and an inability to correlate subjective notions of “high” versus “low” dose ranges between these systems have led to confusion in interpreting the literature [ 102 ]. As shall be discussed below, however, in vivo animal data and clinical observations consistently indicate that high microbial burdens suppress cell-mediated immunity. Therefore, consistent with Metchnikoff's findings at the turn of the 20th century [ 167 ], it can now be strongly asserted that the highest dose ranges, and therefore the highest microbial burdens in infected patients, suppress cell-mediated immunity. At first glance the assertion that high infectious inocula suppress immune responses seems counterintuitive. One might predict that higher microbial burdens would stimulate a greater immune response than lower microbial burdens. However, evolution has adapted the mammalian host to be far more concerned about auto-inflammatory destruction than tissue damage wrought by microbes. Chronic viral hepatitis proves an illuminating model in this regard. It is known that liver necrosis in viral hepatitis is not due to viral cytopathic effect, but rather to CD8 + T-cytotoxic lymphocytes lysing infected host cells to expose intracellular virus [ 168 ]. Acute bursts of type 1 immunity can rapidly interrupt intracellular viral replication and abort infection at the cost of liver necrosis [ 169 , 170 ]. For example, treatment with IFN-α can lead to hepatitis virus clearance in some patients by boosting cell-mediated immunity, leading to acute stimulation of CD8 + T-cytotoxic cell activity [ 171 , 172 ]. But what if the viral burden in the liver is very high? In such cases, the boosted host response leads to tissue necrosis extensive enough to destroy the liver and cause severe morbidity to the host in the process of clearing the virus, a true Pyrrhic victory [ 173–176 ]. In order to prevent this, the mammalian immune system has adapted to suppress cell-mediated immunity when the viral load reaches a certain threshold [ 177 ]. Indeed, patients chronically infected with hepatitis B virus are specifically anergic to the virus, and lowering the viral load with lamivudine has been shown to restore T cell-mediated antiviral effects [ 178 ]. Antigen-presenting cell. The type of antigen-presenting cell stimulating the T cell may also play a role in the polarization of the lymphocyte to a Th2 or Th2 phenotype [ 179 ]. Some studies have reported that B cells are particularly prone to inducing type 2 outcomes [ 180 , 181 ], even in the presence of IL-12 [ 182 ]. This is consistent with their need to drive a type 2 response to feed-forward stimulate their own production of antibody. Conversely, macrophages may be more likely to stimulate type 1 outcomes [ 183 ]. Dendritic cells, acknowledged to be the most potent antigen-presenting cells in the body [ 184–186 ], are capable of driving both type 1 and type 2 outcomes, depending on the local cytokine microenvironment [ 187 ]. Prostaglandins and IL-10 suppress IL-12 production by dendritic cells while stimulating secretion of IL-10, which leads to Th2 polarization of responding lymphocytes [ 188 , 189 ]. Conversely, IFN-γ and microbial fractions such as lipopolysaccharide (LPS) induce dendritic cells to secrete IL-12, stimulating type 1 outcomes [ 187 ]. On the basis of these data from dendritic cell studies, it is now believed that all antigen-presenting cells are capable of stimulating either a type 1 or type 2 outcome, depending on the presence of certain “danger signals” (see below) present in the local microenvironment [ 190 ]. Such danger signals modulate the profile of cytokines secreted by the antigen-presenting cell, which results in polarization of the responding lymphocyte to the Th2 or Th2 phenotype. Strength of signal. The affinity of the T-cell receptor for the MHC/stimulating-antigen complex, the presence of certain costimulatory molecules on the antigen-presenting cell, and the timing of T-cell-receptor ligation by the MHC/antigen complex have each been shown to modify type 1 and type 2 outcomes [ 191–195 ]. There is much confusion in this area, as evidenced by an abundance of conflicting reports on whether high or low affinity, present or absent costimulation, and short or long ligation mediate Th2 or Th2 polarization. This lack of concordance likely reflects study-to-study variation in the complex interactions between these difficult-to-measure variables. The Decision to PolarizeHaving discussed the mechanisms responsible for polarization to Th2 or Th2 responses, we must now consider how the immune system determines which outcome is superior for a given danger signal. Since the cytokines IL-12 and IL-4 are the key factors responsible for inducing polarization of naive T cells toward the Th2 or Th2 profile, the question is raised: what factors tell the immune system to preferentially produce IL-12 or IL-4 at the start of a given immune response? In striking contrast to the prevailing notion of lymphocytes as the “generals” of the immune response and phagocytes as rather obtuse infantrymen, it is now clear that innate immune cells, not T cells, make the “decision” to stimulate a type 1 or type 2 response. Phagocytes instruct T cells to adopt a Th2 or Th2 phenotype by secreting polarizing cytokines, thereby altering the local microenvironment around the newly activated lymphocyte. The information used by innate immune cells to decide which cytokines to secrete include (1) the presence of certain “danger signals” [ 196 ] in the local microenvironment and (2) systemic factors affecting the host at the moment the danger signals are revealed. Microbes contain within them information that directly induces secretion of IL-12 by phagocytic cells. Gram-negative endotoxin, or LPS, and gram-positive cell wall lipotechoic acid bind to nonpolymorphic receptors on innate immune cells and directly induce secretion of IL-12 and other pro-inflammatory cytokines such as IFN-α and IFN-γ [ 197 , 198 ]. Furthermore, bacterial DNA is rich in immunostimulatory sequences [ 199 ]. Well-described immunostimulatory sequences include poly-G sequences and CpG motifs [ 200 , 201 ], which are hexamers of purine-purine-CG-pyrimidine-pyrimidine. Eukaryotic DNA contains very few CpG motifs, and even when they occur in eukaryotic genomes they tend to be methylated. Unmethylated prokaryotic CpG DNA is capable of directly inducing IFN-α and -γ and IL-12 secretion from B-cells, natural killer cells, and monocyte/macrophages [ 202–206 ]. Other innately stimulatory microbial antigenic fractions have also been described, including antigens from Toxoplasma [ 207 ], mycobacteria [ 208 ], and fungi [ 197 ]. Finally, heat shock proteins, which are synthesized in response to cellular stresses in both prokaryotic and eukaryotic cells, are capable of directly inducing IL-12 secretion from innate immune cells [ 197 ]. Even host heat shock proteins induce IL-12, which indicated that the innate immune system is genetically programmed to scan local microenvironments for any sign of danger, even if it is an indirect sign of host tissue destruction rather than direct evidence of a microbial invader [ 209 ]. Microbial characteristics are also capable of direct induction of type 2 immunity. When a phagocyte attempts to ingest a particle larger than itself, the leukocyte reorganizes its cytoskeleton in a reaction termed “frustrated phagocytosis” [ 210 , 211 ]. During this process the leukocyte exocytoses intracellular granules that would normally have fused with the ingested phagosome, spewing these granules toward the uningestible particle [ 212 , 213 ]. The degradative enzymes and microbial peptides that are released are then able to damage the uningestible particle. Meanwhile, genetic transcriptional changes also occur within the innate immune cell as part of the frustrated phagocytosis complex of activities. There is, for example, a marked upregulation of IL-10 secretion and a decreased secretion of IL-12 in neutrophils undergoing frustrated phagocytosis [ 214 ]. Thus innate immune cells exposed to large extracellular pathogens, such as helminths, directly induce a type 2 cytokine environment. Furthermore, as mentioned above, systemic host states at the time of antigen stimulation also modulate type 1/type 2 outcomes. Initial production of IFN-α and IFN-γ by innate immune cells and early responding γδ T cells and natural killer cells can also upregulate the local production of IL-12 [ 197 , 215–218 ], thereby inducing a type 1 response. Conversely, pre-existing IL-4, IL-10, and IL-13 inhibit secretion of IL-12, thereby blocking Th2 polarization [ 197 ]. Elevated catecholamine, glucocorticoid, and estrogen/progesterone levels all directly suppress the development of a local cytokine milieu rich in IL-12, and instead induce IL-4, IL-10, and IL-13. Therefore, hosts who are undergoing physiological stress, are pregnant, or are taking glucocorticoids, cyclosporine, or FK-506 are innately prone to developing type 2 responses, even to antigens that would normally elicit a type 1 response. The Molecular Genetics of PolarizationThe past 5 years have witnessed a revolution in our understanding of the molecular genetics of Th2/Th2 polarization. Specifically, investigators have found that ligation of the IL-12 receptor on Th0 cells activates the transcription factor STAT4 (signal transducer and activator of transcription 4) [ 219 ], which triggers regulatory sequences leading to Th2 polarization [ 220 ]. Conversely, ligation of the IL-4 receptor on Th0 cells triggers activation of STAT6 [ 221 ], which suppresses Th2 polarization and leads to Th2 polarization [ 222 ]. Indeed, mice with germline disruptions of the STAT4 or STAT6 genes are unable to mount type 1 [ 223 , 224 ] or type 2 responses [ 225 , 226 ], respectively. Even more recently, downstream targets of STAT4 and STAT6 have been identified. The transcription factor GATA-3 directly induces Th2 polarization and inhibits Th2 polarization, acting in concordance with STAT6 [ 227–229 ]. Conversely, activation of the transcription factor ERM by STAT4 induces IFN-γ expression [ 230 ]. Most recently, Szabo et al. [ 231 ] identified the penultimate effector of the STAT4-induced Th2 polarization, the transcription factor T-bet. T-bet exerts direct control over IFN-γ gene expression, and ectopic expression of T-bet in already polarized Th2 cells redirects the lymphocytes to adopt a Th2 profile. The reversal of phenotype of an already polarized lymphocyte is particularly intriguing, which suggests the possibility that small molecules can be designed to disrupt the genetic pathways controlling Th2/Th2 polarization. The development of such agents would allow clinicians to intervene in diseases resulting from inappropriate type 1 or type 2 immune responses. SummaryFigure 3 summarizes the processes of Th2 and Th2 induction. Naive Th0 lymphocytes polarize into Th2 cells when they are activated in a microenvironment rich in IL-12. IL-12 is directly induced from innate immune cells by gram-negative LPS, gram-positive lipotechoic acid, prokaryotic CpG DNA motifs, and heat shock proteins, as well as pre-existing DHEA, IFN-α and IFN-γ. Conversely, IL-4, IL-10, corticosteroids and catecholamines directly inhibit newly activated Th0 cells from differentiating into Th2 cells. Figure 3 Summary of Th2/Th2 induction. Cytokines, hormones, and microbial antigens stimulate the innate immune system to produce either IL-12 or IL-4 in the local microenvironment around a newly activated T cell. IL-12 induces Th0 polarization to the Th2 phenotype and inhibits polarization to the Th2 phenotype, whereas IL-4 acts reciprocally. CMI, cell-mediated immunity; CpG, purine-purine-C-G-pyrimidine-pyrimidine DNA hexamer; DHEA, dehydroepiandrosterone; Epi/NE, epinephrine/norepinephrine; HSP, heat shock protein; LTA, lipotechoic acid; LPS, lipopolysaccharide; PG, prostaglandin; estgn/pgstn, estrogen/progesterone; frust. phag., frustrated phagocytosis. Naive Th0 cells exposed to IL-4 differentiate into Th2 cells. Exposure of innate immune cells to large, nonphagocytosable particles induces secretion of IL-4, IL-10, and IL-13. Furthermore, any host state that leads to high levels of circulating catecholamines, glucocorticoids, estrogens, progestins, or prostaglandins will directly induce secretion of IL-4, IL-10, and IL-13 from innate cells and lymphocytes and directly suppress secretion of IFN-γ and IL-12. Exposure of naive Th0 cells to IL-12 inhibits polarization to Th2 cells; however, if both IL-4 and IL-12 are present at the time of naive T cell activation, the effects of the IL-4 will dominate, and a type 2 response will ensue. Relevant Disease Models: Animal ModelsType 1 Protective ModelsLeishmania. The classic model of type 1/type 2 immunity is Leishmania major infection of Balb/C or C57BL mice. Balb/C mice are genetically prone to type 2 immune responses, whereas C57BL mice are prone to type 1 immunity. The genetic mechanisms of these tendencies are not well characterized, but Balb/C mice appear to have a defect in the normal induction of IL-12 [ 232 ], possibly due to a tendency for early hypersecretion of IL-4 [ 233 ]. The result is that newly activated T cells in Balb/C mice are resistant to Th2 polarization and instead become Th2 cells. Sadick and Locksley et al. first reported that Balb/C mice are inherently susceptible to Leishmania [ 234 , 235 ], and quickly thereafter they and others showed that C57BL mice are intrinsically resistant to the organism [ 236 , 237 ]. Subsequent studies confirmed that CD4 cells from susceptible Balb/C mice responded to Leishmania infection by differentiating into Th2 effector cells, which could not protect the mice from infection, whereas C57BL CD4 cells polarized into Th2 cells that abrogated infection [ 238 , 239 ]. Blockade of IL-4 in susceptible Balb/C mice allowed protective type 1 responses to develop, and the mice survived the infection [ 239–241 ]. Conversely, administration of IL-4 or abrogation of IFN-γ in normally resistant C57BL mice caused them to mount futile type 2 responses and succumb to disseminated disease [ 242 ]. Mosmann's group (Krishnan et al. [ 243 ]) reported that pregnant C57BL mice are unable to mount their normal type 1 immune responses because of placental stimulation of IL-4 and IL-10 and suppression of IFN-γ. Such pregnant mice mounted futile type 2 responses and were unable to control Leishmania infections. The evolutionary benefit of suppression of inflammation by the pregnant state was made obvious in a second study by the same group; induction of a type 1 response to Leishmania in infected pregnant mice caused fetal resorption and uterine scarring [ 146 ]. IL-12 must be present during the initial infection in order for protective type 1 responses to develop, but once a population of Th2 cells is established, IL-12 is not required for the cells to mediate protection [ 244 ]. The dispensability of IL-12 after establishment of type 1 responses was strongly supported by a study in which mature Th2 cells adoptively transferred into severe combined immunodeficiency (SCID) mice were able to protect the mice from Leishmania infection without addition of recombinant IL-12 [ 245 ]. As Th2 cells do not actually secrete IL-12 (IL-12 is secreted only by antigen-presenting cells), IL-12 cannot have been necessary for the protective effect of the Th2 cells against infection. Although addition of cytokines or anti-cytokine antibodies at the time of initial infection is able to reverse the type 1/type 2 polarity at the outset of the immune response, it has proved difficult to reverse type 1 or type 2 responses in vivo once they have already been established. Conversely, it has been possible to reverse the phenotype of populations of ex vivo T cells taken from animals with established infection [ 115 , 246 ]. These studies raised an interesting question: if populations of ex vivo T cells taken from mice with established infections can be reverted in vitro, why can't the phenotype of the overall immune response be reversed in vivo? A likely answer was provided by Nabors et al. [ 247 ]. These investigators administered IL-12 with or without a chemotherapy agent to mice with Leishmania infections. Only the combination of IL-12 and the antimicrobial agent was able to reverse the established nonhealing type 2 response in vivo, allowing a healing type 1 response to develop. The implication is that decreasing the antigenic burden of the infected animals was crucial to disinhibiting the animals' type 1 immunity. In concordance with this finding, inoculation of low infectious doses of Leishmania in Balb/C mice induced a type 1 response rather than the expected type 2 response [ 248 , 249 ]. This is consistent with the notion that high infectious inoculations stimulate type 2 immunity, whereas lower inoculations allow protective type 1 inflammation to develop. These results indicate that antimicrobial chemotherapy is a powerful tool for inducing healing type 1 responses in hosts whose normal type 1 immunity is suppressed by overwhelming antigenic burden. Bacterial infections. Pathogenic Escherichia coli and Salmonella typhimurium directly induced IFN-γ in vivo in infected mice. Strains of mice producing higher levels of IFN-γ cleared the microbes up to 10-fold more effectively, making them resistant to infection [ 250 ], whereas IFN-γ gene knockout mice suffered from severe septicemia following oral inoculation [ 251 ]. As well, ex vivo spleen cells taken from mice with acute E. coli pyelonephritis produced IL-2 and IFN-γ but no IL-4 during the first 7 days after infection [ 252 ]. Thereafter, a gradual switch in profiles was noted, such that by several months after infection the level of type 1 cytokines was decreased. This is consistent with the notion that the immune system uses type 1 responses for protection against acute infection and switches to type 2 responses when the danger is passed in order to reestablish homeostasis and protect the host from autoinflammatory destruction. Exogenous IL-12 induced long-lasting protective type 1 immunity in mice infected with Listeria monocytogenes [ 253 , 254 ], and IL-10 −/− knockout mice were resistant to infection by Listeria. Such knockout mice quickly developed more intensely polarized type 1 responses than their wild-type littermates, so that by 48–72 h after infection, their microbial tissue burden was 50-fold lower than that of the wild-type mice [ 255 ]. An elegant study compared early ex vivo γδ T cell cytokines following murine infection by Listeria or the helminth Nippostrongylus. Within several days of infection, Listeria induced γδ T cells to secrete a type 1 profile of cytokines, whereas Nippostrongylus infection induced a rapid secretion of type 2 cytokines [ 256 ]. This is consistent with in vitro data suggesting that intracellular pathogens with innately antigenic fractions induce early IL-12 release from leukocytes, whereas large extracellular pathogens induce frustrated phagocytosis, thereby eliciting a type 2 response. Type 1 responses are also protective against other bacteria, such as Pseudomonas, Yersinia , and Klebsiella [ 257–261 ]. Mycobacterial infections. Type 1 immunity has also been shown to be protective against mycobacteria. Mice inherently resistant to Mycobacterium leprae produced IL-12 early on at the site of infection [ 262 , 263 ], but mice susceptible to M. leprae infection failed to produce early IL-12 [ 262 ]. When IL-12 was administered to mice with established M. leprae infections, bacteria burdens were markedly decreased. Orme et al. studied the evolution of an immune response to tuberculosis in infected mice by pulsing ex vivo CD4 cells with microbial fractions and measuring the resultant cytokines released [ 264 ]. Early during infection, and peaking with the time of maximum protective inflammation, IFN-γ dominated the cytokine response. By 3–5 weeks later, when the infection had been contained and granulomas had begun to organize in vivo, IL-4 and IL-10 dominated the cytokine profile, and IFN-γ was markedly suppressed. This is in concordance with the recurrent theme that type 1 cytokines are expressed during the protective phase of an immune response, and a switch is made to expression of type 2 cytokines during the resolution phase. Fungal infections. Findings in studies of the role of type 1/type 2 immunity in Candida, Coccidioides, Cryptococcus , and Aspergillus infections parallel closely the findings from the Leishmania model: mice susceptible to fungal infections mount type 2 responses to the organisms, but resistant mice mount type 1 responses [ 265–270 ]. Blocking IL-4 or IL-10 at the time of infection of Balb/C mice with Candida increased the level of IFN-γ-induced cell-mediated immunity, which effectively protected these normally susceptible mice from the fungus [ 89 , 271 ]. Indeed, inhibition of IL-4 allowed 81% of mice to survive the infection; none of the untreated control mice survived [ 271 ]. Adding to the notion that high microbial burden suppresses type 1 immunity, normally susceptible mice infected with sublethal inocula of Candida developed type 1 immunity instead of their usual type 2 immune response [ 272 ]. This reversal of immunologic phenotype was due to diminished induction of IL-4 secretion by the lower inoculum. Furthermore, lowering fungal burden in infected mice by treatment with either amphotericin B or fluconazole induced a healing type 1 immune response, an effect potentiated by blockade of IL-4 [ 273 , 274 ]. Therefore, it is the balance of IL-12 and IL-4 induced early after infection that determines the eventual phenotype adopted by the adaptive immune response. High microbial burden tips the balance in favor of IL-4, suppressing cell-mediated immunity and polarizing the immune response toward a type 2 phenotype. Antimicrobial chemotherapy is an effective intervention to favor type 1 immunity by lowering microbial burden. Type 2 Protective ModelsHelminths. The same tendency toward type 2 immune responses that makes Balb/C mice inherently susceptible to bacterial infections makes them inherently resistant to infection by helminths [ 275 ]. In addition, strains of mice prone to type 1 responses, although innately resistant to most bacteria, are inherently susceptible to helminthic infections [ 275 ]. Therefore, unlike every disease model so far discussed, it is type 2 immunity rather than type 1 immunity that protects mammals from helminths [ 275–277 ]. Type 2 responses correlate with diminished worm burden, whereas type 1 responses allow chronic infection and scarring to develop [ 278 ]. Mast cell activation has been shown to be a key component of type 2 immunity to various helminths, including Trichinella and Nippostrongylus [ 279–281 ]. IL-9 is important in mast cell activation, which increases gastrointestinal peristalsis that successfully expels parasites from the gut [ 282 ]. Indeed, transgenic mice overexpressing IL-9 were highly resistant to trichinella infection [ 283 ], and blockade of IL-9 worsened infection in mice normally resistant to trichuris infection [ 284 ]. Abrogation of IFN-γ or administration of exogenous IL-4 in mice susceptible to helminths reversed their normal type 1 immunity, and the resultant type 2 response mediated expulsion of the parasite from the gut [ 285 ]. Conversely, blocking IL-4 or administering IL-12 in normally resistant mice led to the development of futile type 1 responses, which allowed chronic infection to develop [ 285–287 ]. Although the above studies provide convincing evidence that type 2 immunity is protective against helminths, recent revisionist thinking has challenged this notion [ 288 ]. Although conceding that type 2 immunity is the natural mammalian response to helminths, the revisionist theory states that type 2 immunity occurs because helminths deviate the host immune response to a nonprotective posture, enabling the worms to successfully infect the host. The evidence in support of this notion derives from studies in which serum IgE and IL-4 levels have failed to correlate with host protection against helminths [ 289–295 ]. In fact, IL-4 knockout mice are perfectly resistant to Nippostrongylus infection, indicating that IL-4 is not required for protection against this helminth in mice [ 296 ]. The notion that type 2 immunity is a maladaptive response to helminthic infection was directly challenged by an elegant study by Bancroft et al. ( figure 4 ) [ 297 ]. These investigators compared immune responses in wild-type, IL-4 −/− , and IL-13 −/− knockout mice following infection with Trichuris muris . Wild-type mice mounted strong type 2 responses that successfully cleared the helminth. IL-4 knockout mice failed to mount type 2 responses; they produced no IL-4 and had markedly diminished IL-5 and IL-13 levels, which resulted in a huge increase in worm burden. It is interesting that in contrast to IL-4 knockout mice, production of IL-4 and IL-5 by the IL-13 knockout mice was only mildly diminished in comparison with that in wild-type animals, indicating that they still mounted type 2 responses. Nevertheless, despite their apparent type 2 response, the IL-13 knockout mice suffered from twice the worm burden than that in the IL-4 knockout mice. Thus a type 2 immune response is protective against Trichuris only if IL-13 is present. Figure 4 Immunity to Trichuris muris in IL-4 and IL-13 knockout (IL-4 −/− and IL-13 −/− ) mice. Left Y- axis , Ex vivo cytokine production by peripheral blood mononuclear cells; right Y- axis , tissue worm burden (number of worms cultured from cecum and colon). C57BL and 129 are the parent strains of the IL-4 −/− and IL-13 −/− knockout mice, respectively (figure reproduced with permission from [ 297 ]). IL-4 is a key inducer of type 2 immunity, but IL-13 can mimic some of IL-4's function by binding to a shared IL-4/IL-13 receptor [ 298–300 ]. Furthermore, much like IL-12 induces type 1 immunity but IFN-γ actually mediates type 1 effects, IL-13 appears to be more important than IL-4 for the actual protective effect of type 2 immunity against helminths. Indeed, whereas IL-4 knockout mice expel Nippostrongylus normally from the gut, IL-13 knockout mice and IL-4/IL-13 double-knockout mice are extremely susceptible to Nippostrongylus infection [ 301 , 302 ]. An overwhelming majority of data indicate that type 2 immunity is the key to mammalian protection against infection by helminths. IL-4 is important for induction of type 2 immunity, but IL-5, IL-9, and IL-13 are the key effector cytokines in type 2-mediated protection. IL-5 and IL-9 act via eosinophil and mast cell stimulation. Although it has been suggested that IL-13 acts via secondary induction of TNF [ 303 ], its definitive mechanism remains obscure. Relevant Disease Models: Clinical DiseasesLeishmania. The findings of studies of immunity in patients infected with Leishmania parallel the data generated in animal models. mRNA analysis of cutaneous lesions caused by Leishmania braziliensis demonstrated 2 profiles in human patients [ 304 ]. Biopsy specimens from patients with localized disease displayed prominent mRNA coding for IL-2, IFN-γ, and LT-α, consistent with a protective type 1 immune response. Biopsies of lesions from patients suffering from destructive mucocutaneous American leishmaniasis demonstrated a marked increase in the level of IL-4 mRNA, which is consistent with a failed type 2 host immune response. Analogous to murine data on infectious burden, expression of IL-10 was found to be higher in patients with active Leishmania donovani infections than in patients who had been cured of disease [ 305 ]. T cells from patients who had recovered from limited Leishmania infections expressed high levels of IFN-γ and LT-α, but little or no IL-4, when exposed in vitro to Leishmania antigens [ 306 ]. Conversely, ex vivo cytokine production by lymphocytes taken from patients with severe visceral leishmaniasis was dominated by the type 2 cytokines IL-4 and IL-10 [ 307 ]. Thus type 1 immunity is the key to protection against Leishmania infections in humans, and a high infectious burden suppresses the human immune system from mounting type 1 responses. Bacterial infections. Direct examination of cytokine profiles of patients infected with Haemophilus influenza and Streptococcus pyogenes revealed that IFN-γ and LT-α were the dominant cytokines elicited at the site of infection, and no IL-4 was found [ 308 ]. Similarly, Lactobacillus, S. agalactiae , S. pyogenes , and Listeria directly induced IL-12 and IFN-γ but not IL-4 secretion from human leukocytes [ 309–311 ]. Case reports concerning patients with identified genetic defects in cytokine or cytokine receptor genes are illustrative of the role of cytokines in host defense against infection. For example, patients with defects in the IFN-γ, IL-12, or IL-12-receptor genes are unable to produce IL-12 and/or IFN-γ and as a result have developed severe infections caused by Salmonella [ 312 , 313 ], Streptococcus , or Listeria [ 314 , 315 ]. Mycobacterial infections. The dichotomy between patients with lepromatous leprosy, which is the disseminated, severe form of the disease, and those with tuberculoid leprosy, which is local disease controlled by the immune system, parallels in vivo cytokine production [ 316 ]. Lepromatous leprosy develops in patients who mount type 2 immune responses to the organism, whereas tuberculoid leprosy is synonymous with a successful type 1 immune response to M. leprae [ 164 , 317 ]. Mononuclear cells from lepromatous leprosy patients secreted high levels of prostaglandin E and IL-10, thereby suppressing IL-12 induction of IFN-γ, whereas cells from tuberculoid leprosy patients did not secrete prostaglandin E and IL-10 [ 164 ]. Furthermore, lesion-biopsy specimens from patients with tuberculoid leprosy contained Th2 cells expressing 10-fold higher levels of IL-12 mRNA than in lepromatous patients [ 316 ]. Conversely, biopsy specimens from lepromatous patients contained high levels of IL-4 and IL-10. There is also a dichotomy between a high humoral response and a high DTH response among patients infected with Mycobacterium tuberculosis [ 318 , 319 ]. Patients with active tuberculosis have been shown to have diminished DTH reactions, cell proliferation, and IFN-γ production in response to PPD, as well as higher levels of antimycobacterial antibodies, than do PPD-positive, uninfected case control subjects [ 320 ]. In addition, infected patients produced higher levels of IL-4 [ 321 , 322 ]. These data are consistent with the notion that active M. tuberculosis infection was related to dominant type 2 immunity, whereas protected patients mounted type 1 immune responses to the organism. Multiple published case reports of severe mycobacterial infections in patients with genetic IFN-γ or IL-12 deficiencies confirm the importance of type 1 immunity in protection against these organisms [ 312 , 313 , 315 , 323–327 ]. As in mice, immunity to mycobacteria in humans evolves over time ( figure 5 ) [ 328 ]. Within 5 days after BCG vaccination, leukocyte production of IL-2, IFN-γ, and LT-α was shown to increase dramatically, whereas production of Th2 cytokines remained minimal. By a week after inoculation, the production of Th2 cytokines reached a plateau and there was a sudden burst in IL-4 production. By days 10–12 after vaccination, there was a remarkable suppression of type 1 cytokine activity and a rise in IL-5 and IL-10 production. This elegant study provided powerful confirmatory evidence that type 1 immunity is directly induced by mycobacteria and that the immune system naturally switches over time to a type 2 immune response in order to reestablish homeostasis after the battle is won. Figure 5 Change in cytokine pattern over time following BCG vaccination in humans. Ex vivo peripheral blood mononuclear cells (PBMCs) were analyzed by fluorescence-activated cell-sorting (FACS) for intracellular cytokine production on sequential days following administration of BCG vaccine to healthy volunteers. The percentage of mononuclear cells expressing type 1 cytokines (IL-2, IFN-γ, lymphotoxin [LT]-α) is shown on the left y axis, and the percentage of cells expressing type 2 cytokines (IL-4, IL-5, IL-10) is shown on the right y axis (figure reproduced with permission from [ 328 ]). Fungal infections. Similar to antigenic fractions from typical bacteria, certain Candida antigens directly induced secretion of IL-2 and IFN-γ, but not IL-4 and IL-10, from human leukocytes [ 329 ]. It is interesting that patients with chronic mucocutaneous candidiasis seem refractory to the normal induction of IL-2 and IFN-γ. Cells from such patients produced an altered profile of cytokines, more reminiscent of a type 2 profile, when stimulated in vitro with Candida antigens [ 330 ]. Since IL-4 inhibits human phagocytes from killing Candida [ 331 ], this switch to a type 2 profile can explain the inherent susceptibility of such patients to candidal infections. The importance of IFN-γ and type 1 immunity in host defense against fungal infections is made clear by observations of patients with chronic granulomatous disease. Such patients suffer from an inability to generate a respiratory burst in phagocytic cells and therefore commonly develop invasive pyogenic and fungal infections, often caused by Aspergillus [ 332 ]. Treatment with recombinant IFN-γ stimulates killing of fungi by phagocytes of patients with chronic granulomatous disease [ 333 ] and thereby reduces the frequency and severity of clinically apparent fungal infections [ 334 ]. Therefore, IFN-γ, and by extension type 1 immunity, is protective against fungal infections. HIV. Numerous studies have found that during the progression of AIDS, mononuclear cells lose the ability to secrete IL-2, IL-12, and IFN-γ and produce increased levels of IL-4 and IL-10 [ 335–340 ]. Because of the loss of IL-2 secretion, T cells from HIV-positive patients are typically unable to proliferate when stimulated by common antigens. However, addition of recombinant IL-12 to in vitro cultures of T cells restored not only the lymphocytes' ability to proliferate but also their production of IL-2 and IFN-γ [ 341 ]. Analyses of the impact of highly active antiretroviral therapy on immune reconstitution in patients with AIDS have been recently published [ 342 , 343 ]. Investigators reported that potent inhibition of viral replication reversed the suppression of IL-2 and IFN-γ production in the patients' leukocytes while markedly diminishing their overproduction of IL-4 and IL-10. This paralleled a recovery in T cell counts. Similar results have been found in studies of children treated with highly active antiretroviral therapy [ 344 ]. Therefore, clinicians may be able to reverse the immune dysregulation in patients with AIDS by affecting viral suppression. Th2 cells express the chemokine receptor CCR5, whereas Th2 cells express the CXCR4 receptor [ 345–347 ]. M-tropic strains of HIV, which are the infectious particles, use CCR5 as a co-receptor for viral entry into the host cell, whereas T-tropic HIV strains, which emerge as the dominant strains during the progression of AIDS, use CXCR4 [ 348 , 349 ]. This switch in receptor usage during disease progression parallels the frequency with which Th2 and Th2 cells are found in vivo. Thus part of the pathogenesis of AIDS is a selective loss of Th2 cells, which then forces the virus to adapt to infect Th2 cells in order to persist in the host. Although suppression of IL-12 production by phagocytes is one mechanism by which HIV acts to suppress type 1 immunity, in vivo studies have demonstrated an additional effect. Hormonal abnormalities, such as a loss of serum testosterone derivatives, are commonly seen in patients with AIDS and result in lean-muscle-mass wasting [ 350–352 ]. In fact, decreases in serum DHEA were linearly related to loss of CD4 cells during AIDS progression [ 353 , 354 ], and patients with serum DHEA levels <180 ng/mL had a 2.3 RR for progression to AIDS within 2 years [ 355 , 356 ]. Conversely, loss of CD4 cells and AIDS progression were inversely correlated with serum cortisol levels [ 350 , 354 , 357 ]. Therefore, AIDS is associated with hormonal conditions—namely, low DHEA and high glucocorticoid levels—which suppress IL-2, IFN-γ, and IL-12 production and stimulate IL-4 and IL-10 production [ 358 ]. This is the perfect recipe for systemic suppression of type 1 responses and stimulation of type 2 responses. These studies provide the theoretical underpinning for the hypothesis that HIV induces a gradual paralysis of type 1 immunity, allowing expansion of Th2 cells at the expense of naive T cells and Th2 cells. This theory was confirmed by clinical observations in several key studies. As IgE is a highly specific bioassay for type 2 immune responses, Viganó et al. compared serum levels of IgE in 58 vertically infected HIV-positive children and 35 serorevertant control subjects ( figure 6 ) [ 359 , 360 ]. They found that HIV-positive children had significantly higher levels of IgE antibody than did the serorevertants, and 75% of the children whose IgE levels were abnormally high had a precipitous drop (by ⩾30%) in their CD4 counts over the subsequent year. Therefore, HIV-positive children suffer from dysregulated immunity in which type 2 responses overwhelm type 1 responses, and the rate of loss of type 1 immunity parallels the loss of T helper cells. Figure 6 Ex vivo cytokine production by peripheral blood mononuclear cells and serum IgE levels in 58 vertically infected children with HIV infection or AIDS, compared to that in 35 serorevertant HIV-negative control subjects (figure reproduced with permission from [ 359 , 360 ]). HIV is unique among the disorders so far discussed in that several interventional cytokine trials involving humans have been performed. Kovacs et al., for example, published an impressive randomized trial of IL-2 plus zidovudine versus zidovudine alone in the treatment of 60 patients with AIDS [ 361 ]. After a year of follow-up, the CD4 cell counts of patients in the IL-2 group doubled from a mean of 428 cells/μL to 916 cells/μL, whereas those of the patients treated with zidovudine alone dropped from a mean of 406 cells/μL to 329 cells/μL. There was no difference in the viral load between the 2 groups at the end of the year. Thus the difference in T helper cell counts at the end of the year was unrelated to the degree of viral suppression. Rather, the exogenous IL-2 restored the immune system's ability to produce more peripheral T cells, a finding confirmed by more recent clinical trials [ 362–364 ]. Smaller studies of subcutaneous IL-2 in HIV-infected patients by Davey et al. [ 365 ] and De Paoli et al. [ 366 ] yielded similar results. The latter study examined the effect of IL-2 on naive T cells, identified by staining for the surface marker CD45RA. Like Kovacs et al. [ 361 ], De Paoli et al. [ 366 ] reported a doubling of CD4 cell counts at 1 year in AIDS patients treated with IL-2 and antiretrovirals and no significant change in the CD4 counts of patients treated with antiretroviral therapy alone. Like the total T cell population, the numbers of naive T cells also doubled in the IL-2-treated patients, whereas there was no change in the number of naive T helper cells in the group treated with antiretrovirals alone. Therefore, IL-2 not only enables activation of and expansion of the number of Th2 effector cells but also promotes survival of naive Th0 cells in patients with AIDS. In addition, Khatri et al. [ 367 ] studied ex vivo cytokine production by T cells in patients with AIDS who were treated with IL-2. They reported that the patients' T cells produced twice as much IFN-γ and half as much IL-10 during the IL-2 therapy as they did before or after treatment. The final proof of a shift from type 1 to type 2 immunity in patients with AIDS derives from an elegant study by Norbiato et al. [ 368 ]. These investigators studied 10 patients with AIDS who developed Addisonian symptoms and were found to be glucocorticoid-resistant, as determined by low-affinity binding of their glucocorticoid receptors to dexamethasone. The glucocorticoid-resistant AIDS patients were compared to 10 case-control AIDS patients with normal steroid receptors and 10 HIV-negative control subjects. Glucocorticoid-resistant AIDS patients had urinary cortisol levels 5 times higher than those in the HIV-negative patients. However, because their resistance to cortisol spared them from its immunosuppressive effects [ 369 ], T cells from the glucocorticoid-resistant patients were able to secrete high levels of IL-2 and maintain a normal ratio of serum IFN-γ to IL-4 ( figure 7 ). Figure 7 Twenty-four-hour urine cortisol, serum cytokine, and serum IgE levels in glucocorticoid-resistant patients with AIDS (AIDS-GR) and glucocorticoid-susceptible control patients with AIDS (AIDS-GS) and HIV-negative control subjects (HIV − ; figure reproduced with permission from [ 368 ]). Conversely, although patients with AIDS who had normal steroid receptors had urinary cortisol levels somewhat lower than those of the steroid-resistant patients with AIDS, the cortisol completely suppressed endogenous IL-2 production in these patients ( figure 7 ). This loss of IL-2 secretion almost totally abrogated IFN-γ production, whereas IL-4 and IL-10 production were strongly upregulated. A comparison of serum IgE levels in the cortisol-resistant and normal-receptor patients with AIDS closes the argument. The IgE levels of glucocorticoid-resistant patients with AIDS were barely elevated in comparison with those of HIV-negative control subjects, which indicates an essentially normal ratio of in vivo type 1/type 2 immunity. Conversely, patients with AIDS with normal steroid receptors had IgE levels 100-fold higher than those of HIV-negative control subjects. Clearly, these patients with AIDS were suffering from an overwhelming excess of type 2 immunity. Thus in vitro and in vivo data indicate that HIV, beyond simply killing T cells, disrupts normal homeostasis of type 1 and type 2 immunity. Abnormally high levels of glucocorticoids and suppressed levels of DHEA, along with direct viral suppression of IL-12 production, create a host environment that suppresses differentiation of type 1 effector cells and stimulates development of type 2 immune responses that are ineffective at controlling a broad range of pathogens. Relevant Disease Models: Type 1/Type 2 HomeostasisAs repeatedly discussed, the immune system restores homeostasis by switching a type 1 response into a type 2 response once an infection has been cleared. Recent data from Gett and Hodgkin shed new light on the mechanism of this switch [ 370 ]. These investigators developed a sophisticated experimental system to determine how many cell divisions a given T cell had undergone after activation. They simultaneously measured in vitro cytokine production by the lymphocytes, allowing correlations to be drawn between cell division number and cytokine production ( figure 8 ). Figure 8 Cytokine secretion as a function of T cell division. In vitro-activated murine T lymphocytes were stained with an intracellular fluorescent dye whose intensity decreases with each cell division. FACS was used to sort lymphocytes into populations of equivalent cell-division number. The cultures were restimulated with anti-CD3 antibody, and cytokines in the supernatants were analyzed by ELISA, allowing cytokine production to be matched to T cell division number (figure reproduced with permission from [ 370 ]). Immediately after activation of naive T cells, only IL-2 was produced. During the subsequent cell divisions, polarization began to occur, and IFN-γ was first secreted at cell division number 4. IL-4 secretion began at division 6, accompanied by the gradual waning of IL-2 secretion. IFN-γ production reached a plateau by cell division 7, at which time IL-4 production began to logarithmically increase. Finally, at cell division 8, there was a sharp burst in production of IL-10. Unfortunately, the limit of the technology is about 8 cell divisions. However, with a sudden upswing in IL-10 production at division 8, it can be hypothesized that cell divisions occurring beyond 8 would be associated with a loss of IFN-γ secretion and the establishment of a polarized Th2 profile of IL-4 and IL-10 secretion. Thus there is a molecular genetic basis for the clinical phenomenon of switching from a type 1 to a type 2 response over time during infection. T cells appear to gradually lose the ability to secrete pro-inflammatory cytokines as they mature after multiple cell divisions. Vaccines and Immunotherapy: Paradox and PromiseClinicians traditionally measure vaccine-induced protective immunity by following antibody titers. Furthermore, passive immunization, or administration of exogenous antibody, mediates protection against a variety of infections. Thus, although the model outlined above indicates that type 1 responses are the keys to protection against most infections, paradoxical observations suggest that vaccines and passive immunization rely on type 2 immunity to mediate protection. Three concepts resolve this paradox, fitting the mechanisms of vaccines and passive immunization with the type 1/type 2 model. The first concept is that type 1 immunity does not actively suppress antibody responses. Although titers are lower in dominant type 1 responses than in type 2 responses, Th2 cells are quite capable of inducing antibody production by B cells [ 13 ]. Thus antibody production is consistent with either a type 1 or type 2 response, depending on the subtypes of antibody present. The IFN-γ produced by Th2 cells causes antibody class switching from IgM to the IgG1 and IgG3 subtypes, rather than the IgG2, IgG4, and IgE that are induced by IL-4. IFN γ-induced IgG1 and IgG3 bind avidly via their Fc portions to the Fcγ receptor of phagocytes. Thus, by serving as opsonins, antibody induced during a type 1 immune response synergistically increases the effectiveness of cell-mediated immunity. The second concept is that type 2 immunity, in addition to inducing antibody, actively suppresses cell-mediated immunity. Thus administration of exogenous antibody is not equivalent to induction of a type 2 immune response. Rather, passive immunization with exogenous antibody garners the immunologic benefit of a humoral response without the added deficit of suppressing cell-mediated immunity. Instead, passive immunization synergizes with type 1 immunity by providing extra opsonins to assist activated phagocytes. Passive immunization therefore does not fit into either the type 1 or type 2 description of endogenous immunity. This is logical, since passive immunization is obviously not a normal, physiological component of mammalian immune systems. Although antibody titers are used clinically to determine the efficacy of vaccines, this correlation of high titers with protective immunity cannot be reliably interpreted as an indication that vaccines work via induction of type 2 immunity. Although there is an inverse relationship between the degree of cell-mediated and humoral immunity elicited by a given antigen, the ratio of type 1/type 2 immunity can range from highly polarized to equivalent ( figure 1 ). Indeed, Parish demonstrated 2 zones of humoral and cell-mediated equivalency in his seminal article [ 3 ]. Thus the third concept is that since most experimental studies of vaccines examine only the humoral response, and clinically there are no useful cell-mediated immune assays, the correlation of high antibody titers with protective immunity cannot be interpreted in terms of the type 1/type 2 paradigm. There is no way to know to what degree, on the scale demonstrated by Parish [ 3 ], a given vaccine tilts the balance of type 1/type 2 immune response in a patient. High antibody titers might reflect a state of type 1/type 2 equivalency, or they might reflect stimulation of antibody by Th2 cells rather than Th2 cells. Indeed, antibody induced by vaccines may be of the IgG1 or IgG3 isotype, consistent with a type 1 immune profile [ 371 ]. Only after directly analyzing cytokine patterns elicited by vaccines or concurrently studying humoral and cell-mediated responses can one comment on the relative effects of a vaccine on inducing type 1/type 2 immunity. When such studies have been undertaken, a dominance of type 1 immunity has been found to be elicited by vaccines [ 371 , 372 ]. Type 1 outcomes generate both cell-mediated and humoral responses that act synergistically, whereas type 2 outcomes generate humoral responses but actively suppress cell-mediated responses. Thus the type 1/type 2 immunity model indicates that vaccines intended for virtually all infections, save those directed at large, nonphagocytosable eukaryotes, should be designed to skew the induced response toward a type 1 profile. Multiple mechanisms to mediate vaccine-induced type 1 polarization have been described, including the use of IFN-γ and IL-12 as vaccine adjuvants [ 373–376 ] and the inclusion of genes coding for IFN-γ, IL-12, or CpG motifs in DNA vaccines [ 377–381 ]. In animal models, vaccines inducing type 1 immunity have been proven highly effective at preventing infections, whereas vaccines inducing type 2 immunity increase susceptibility to infection [ 270 , 373 , 374 , 380 , 382–386 ]. Conclusions: A Unifying HypothesisType 1 immunity is the default response to all infections by normal inocula of intracellular or phagocytosable microbes occurring in nonimmunosuppressed hosts. Type 1 immune responses clear such pathogens, thereby diminishing further antigenic stimulation for type 1 immunity. In addition, T lymphocytes naturally switch from production of type 1 cytokines to production of type 2 cytokines as they progress through multiple cell divisions. Therefore, over time a type 1 immune response will tend to convert into a type 2 response, allowing homeostasis to be reestablished. However, with persistent antigenic stimulation—for example, if the type 1 immune response is never able to completely clear the infection—continual stimulation of T cells can induce chronic type 1 responses, leading to host tissue destruction. Conversely, type 2 immunity is the default response to infections by large, extracellular pathogens that cannot be phagocytosed, such as helminths. Type 2 immunity naturally develops over time from type 1 immune responses. However, in patients who have excess sympathetic stimulation before infection, have excess glucocorticoids or high estrogen or progestin levels, are IL-2-deficient because of cyclosporine or FK-506, or are inoculated by an overwhelming microbial burden, the usual type 1 response is suppressed and a type 2 response occurs instead. Clinical factors that induce glucocorticoid or sympathetic responses will tend to make patients susceptible to infections that would normally be dealt with by type 1 immune responses. Malnutrition has been shown to suppress serum DHEA levels and directly induce high systemic levels of glucocorticoids and catecholamines [ 387–390 ], as has the presence of malignancy, even independently of malnutrition [ 391 ]. Indeed, patients with malignancies are prone to type 2 immunity at the expense of type 1 responses [ 392 , 393 ]. Furthermore, the clinical conditions of congestive heart failure [ 394–396 ], chronic obstructive pulmonary disease [ 397 ], and hepatic cirrhosis [ 398 ] are all associated with hypersympathetic stimulation and high circulating catecholamine levels, conditions suppressive to type 1 immunity. Finally, severe systemic stresses induced by traumatic injury [ 399 , 400 ], extensive surgery [ 401 , 402 ], and the use of total parenteral nutrition [ 403 ] have been shown to suppress type 1 immunity and favor type 2 immunity. The implications for clinicians from these data are three. First, the paradigm of type 1 and type 2 immunity provides a pathophysiological explanation for why patients with the above systemic ailments are prone to severe infections. Second, the model suggests new potential weapons in the clinical battle for host defense. For example, the utilization of β-blockers to reverse catecholamine-induced suppression in patients such as those with AIDS, trauma, congestive heart failure, or cirrhosis or those in intensive care units is intriguing. We are unaware of any published study reports describing the incidence of infections in patients receiving β-2 agonist bronchodilators, catecholamine pressors, or β-blockers for heart failure or hypertension. Such data would be invaluable in the study of host immunity to infection and could easily be obtained by careful reporting of the incidence of infections in future clinical trials of β-2 agonists, pressors, or β-blockers. Third, the model explains an important and previously unknown effect of antimicrobial chemotherapy: lowering antigenic burden by treating with antibiotics disinhibits protective type 1 immunity. Reports have already been published of phase I/II clinical trials utilizing several different type 1/type 2 cytokines to polarize patients' immune responses toward appropriate phenotypes. Early studies on the use of IL-2 and IL-12 in humans revealed their potential for severe systemic adverse effects [ 404 , 405 ]. Despite the initial setbacks in patients with cancer, the use of newer schedules of dosing of IL-2 and IL-12 have demonstrated impressive effects in patients with infectious diseases. The use of low-dose adjuvant IL-2 in patients with multidrug-resistant tuberculosis led to a 60% cure rate in these difficult-to-treat patients [ 406 ], and the benefits of IL-2 for patients with AIDS have already been described. In addition, IL-12 has demonstrated antiviral effects with minimal toxicity in patients with chronic hepatitis [ 407 , 408 ]. Conversely, the anti-inflammatory effects of IL-10 in humans [ 409–411 ] have led to its use in hyperinflammatory states ranging from psoriasis [ 412 ] to organ transplantation immunosuppression [ 413 ] to Crohn's disease [ 414 ], with promising results. Blockade of cytokine effects has also been attempted. Specifically, inhaled recombinant IL-4 receptor has shown promise as an anti-asthmatic agent, serving to soak up IL-4 in the airways [ 415 ]. Finally, as mentioned earlier, the targeted design of small molecules capable of disrupting or inducing transcription factors regulating Th2/Th2 polarization may provide an additional set of clinical weapons to intervene in pathological states resulting from aberrant type 1 or type 2 immunity. However, exogenous administration of cytokines is a systemic intervention, whereas the immune system normally regulates itself on the basis of the cytokine milieu present at local microenvironments. Clinicians must develop techniques to administer cytokines in a localized fashion rather than flooding the vascular compartment with them. Such techniques might include the inclusion of genes coding for IL-12 or CpG motifs in DNA vaccines against microbes and the use of liposomally coated cytokines targeted toward in vivo–activated leukocytes [ 416 , 417 ]. AcknowledgmentsWe acknowledge Drs. Scott Filler and Michael Yeaman for their invaluable suggestions and insightful input. References1 . , Immunity in infective diseases , 1905 Cambridge Cambridge University Press Binnie, FG, trans. Reprint: The sources of science, no. 61. New York: Johnson Reprint Corporation, 1968 2 . , Collected studies in immunity , 1905 New York John Wiley & Sons 2a , . , . The classification of allergic reactions underlying disease , Clinical aspects of Immunology , 1963 Oxford Blackwell Scientific Publications (pg. 317 - 37 ) 3 . Immune response to chemically modified flagellin. II. Evidence for a fundamental relationship between humoral and cell-mediated immunity , J Exp Med , 1971 , vol. 134 (pg. 21 - 47 ) 4 , . Immune response to chemically modified flagellin. III. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin , J Exp Med , 1972 , vol. 135 (pg. 298 - 311 ) 5 . Immune response to chemically modified flagellin. IV. Further studies on the relationship between humoral and cell-mediated immunity , Cell Immunol , 1973 , vol. 6 (pg. 66 - 79 ) 6 , . Specific inhibition of antibody formation during immunological paralysis and unresponsiveness , Nature , 1959 , vol. 184 (pg. 1080 - 2 ) 7 . Specific inhibition of antibody production , Immunol , 1962 , vol. 5 (pg. 161 - 8 ) 8 . Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen , Immunol , 1962 , vol. 5 (pg. 378 - 88 ) 9 . Induction of immunological paralysis in two zones of dosage , Proc Roy Soc B , 1964 , vol. 161 (pg. 275 - 92 ) 10 , , , et al. Peritoneal exudate T lymphocytes with specificity to sheep red blood cells. I. Production and characterization as to function and phenotype , Immunology , 1979 , vol. 36 (pg. 691 - 8 ) 11 , , , et al. Peritoneal exudate T lymphocytes with specificity to sheep red blood cells. II. Inflammatory helper T cells and effector T cells in mice with delayed-type hypersensitivity and in suppressed mice , Immunology , 1979 , vol. 38 (pg. 51 - 5 ) 12 , , . Dissociative effects of malarial infection on humoral and cell-mediated immunity in mice , Immunology , 1979 , vol. 37 (pg. 35 - 44 ) 13 , , , et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins , J Immunol , 1986 , vol. 136 (pg. 2348 - 57 ) 14 , . Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones , J Immunol , 1987 , vol. 138 (pg. 3688 - 94 ) 15 , , , et al. Functional heterogeneity among human inducer T cell clones , J Immunol , 1988 , vol. 140 (pg. 4211 - 6 ) 16 , , , et al. Clonal analysis of functionally distinct human CD4 + T cell subsets , J Exp Med , 1988 , vol. 168 (pg. 1659 - 73 ) 17 , , , et al. Lectin-mediated induction of IL-4-producing CD4 + T cells , J Immunol , 1991 , vol. 146 (pg. 577 - 84 ) 18 , . Single IL-2-secreting precursor CD4 T cell can develop into either Th2 or Th2 cytokine secretion phenotype , J Immunol , 1994 , vol. 153 (pg. 3514 - 22 ) 19 , . Acquisition of lymphokine-producing phenotype by CD4 + T cells , Annu Rev Immunol , 1994 , vol. 12 (pg. 635 - 73 ) 20 , , . Human Th2 and Th2 cells: functional properties, mechanisms of regulation, and role in disease , Lab Invest , 1994 , vol. 70 (pg. 299 - 306 ) 21 , , , et al. Lethal tuberculosis in interleukin-6-deficient mutant mice , Infect Immun , 1997 , vol. 65 (pg. 4843 - 9 ) 22 , , , et al. IL-6 is required for the development of Th2 cell-mediated murine colitis , J Immunol , 2000 , vol. 164 (pg. 4878 - 82 ) 23 , , , et al. IL-10 is produced by subsets of human CD4 + T cell clones and peripheral blood T cells , J Immunol , 1992 , vol. 149 (pg. 2378 - 84 ) 24 , , , et al. Differential regulation of IL-13 and IL-4 production by human CD8 + and CD4 + Th0, Th2 and Th2 T cell clones and EBV-transformed B cells , Int Immunol , 1995 , vol. 7 (pg. 1405 - 16 ) 25 , . Regulatory T cells and inflammatory bowel disease , Immunol Today , 1999 , vol. 20 (pg. 442 - 5 ) 26 . Do suppressor T cells exist? , Scand J Immunol , 1988 , vol. 27 (pg. 247 - 50 ) 27 , . Saying the “S” word in public , Immunol Today , 1993 , vol. 14 (pg. 523 - 5 ) 28 , . The third function of the thymus , Immunol Today , 2000 , vol. 21 (pg. 95 - 9 ) 29 , , , et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency , N Engl J Med , 1981 , vol. 305 (pg. 1425 - 31 ) 30 , , . Two distinct non-T helper type 2 interleukin-4 + cell subsets in mice as revealed by single-cell cytokine analysis , Eur J Immunol , 1994 , vol. 24 (pg. 549 - 57 ) 31 , . Generation, persistence, and modulation of Th0 effector cells: role of autocrine IL-4 and IFN-gamma , J Immunol , 1998 , vol. 160 (pg. 5280 - 7 ) 32 , , , et al. A new murine CD4 + T cell subset with an unrestricted cytokine profile , J Immunol , 1989 , vol. 143 (pg. 518 - 25 ) 33 , , , et al. Heterogeneity of mouse helper T cells: evidence from bulk cultures and limiting dilution cloning for precursors of Th2 and Th2 cells , J Immunol , 1990 , vol. 144 (pg. 1629 - 39 ) 34 , , , et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis , Science , 1994 , vol. 265 (pg. 1237 - 40 ) 35 , , , et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-β1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients , J Clin Invest , 1996 , vol. 98 (pg. 70 - 7 ) 36 , , , et al. A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB (low) CD4 + T cells , J Exp Med , 1996 , vol. 183 (pg. 2669 - 74 ) 37 , , , et al. Oral administration of myelin induces antigen-specific TGF-β1 secreting T cells in patients with multiple sclerosis , Ann NY Acad Sci , 1997 , vol. 835 (pg. 120 - 31 ) 38 , , , et al. A CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , Nature , 1997 , vol. 389 (pg. 737 - 42 ) 39 , , , et al. Interleukin 10 secretion and impaired effector function of major histocompatibility complex class II-restricted T cells anergized in vivo , J Exp Med , 1998 , vol. 187 (pg. 177 - 83 ) 40 , . Effects of interferons, interferon inducers and growth factors on phagocytosis measured by quantitative determination of synthetic compound ingested by mouse bone marrow-derived macrophages , Archivum Immunologiae et Therapiae Experimentalis , 1988 , vol. 36 (pg. 537 - 45 ) 41 , , , et al. The effect of tumor necrosis factor-alpha and interferon-gamma on neutrophil function , J Surg Res , 1989 , vol. 46 (pg. 322 - 6 ) 42 , . Molecular basis for the enhanced respiratory burst of activated macrophages , Fed Proc , 1985 , vol. 44 (pg. 2927 - 32 ) 43 , , , et al. Induction of phagocyte cytochrome b heavy chain gene expression by interferon gamma , Proc Natl Acad Sci USA , 1988 , vol. 85 (pg. 5215 - 9 ) 44 , , . Disparate effects of interferon-gamma and tumor necrosis factor-alpha on early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro , J Clin Invest , 1991 , vol. 87 (pg. 711 - 20 ) 45 , , , et al. IFN-gamma-mediated control of Coxiella burnetii survival in monocytes: the role of cell apoptosis and TNF , J Immunol , 1999 , vol. 162 (pg. 2259 - 65 ) 46 , , . Survival of group B streptococcus type III in mononuclear phagocytes: differential regulation of bacterial killing in cord macrophages by human recombinant gamma interferon and granulocyte-macrophage colony-stimulating factor , Infect Immun , 2000 , vol. 68 (pg. 2167 - 70 ) 47 , , . Three distinct classes of regulatory cytokines control endothelial cell MHC antigen expression: interactions with immune γ-interferon differentiate the effects of tumor necrosis factor and lymphotoxin from those of leukocyte α and fibroblast β-interferons , J Exp Med , 1988 , vol. 167 (pg. 794 - 804 ) 48 , . Tumor necrosis factor and immune interferon synergistically increase transcription of HLA class I heavy- and light-chain genes in vascular endothelium , Proc Natl Acad Sci USA , 1990 , vol. 87 (pg. 5183 - 7 ) 49 , , , et al. The influence of interferon-gamma and various phagocytic stimuli on the expression of MHC-class II antigens on human monocytes: relation to the generation of reactive oxygen intermediates , Immunol Lett , 1986 , vol. 13 (pg. 209 - 14 ) 50 , , . Antigen presentation in brain: MHC induction on brain endothelium and astrocytes compared , Immunology , 1987 , vol. 60 (pg. 453 - 9 ) 51 , , , et al. The chemokine repertoire of human dermal microvascular endothelial cells and its regulation by inflammatory cytokines , J Invest Dermatol , 1997 , vol. 108 (pg. 445 - 51 ) 52 , , , et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes , J Invest Dermatol , 1998 , vol. 111 (pg. 645 - 9 ) 53 , , , et al. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES and interleukin-8 genes by inflammatory cytokines , J Biol Chem , 1993 , vol. 268 (pg. 5834 - 9 ) 54 , , , et al. Th2- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts , Am J Respir Cell Mol Biol , 1999 , vol. 20 (pg. 777 - 86 ) 55 , . Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin , J Am Acad Dermatol , 1994 , vol. 30 (pg. 535 - 46 ) 56 , , , et al. Interleukin 4 induces synthesis of IgE and IgG4 in human B cells , Eur J Immunol , 1989 , vol. 19 (pg. 1311 - 5 ) 57 , . IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells , J Immunol , 1994 , vol. 152 (pg. 1094 - 102 ) 58 , . Mouse IL-13 enhances antibody production in vivo and acts directly on B cells in vitro to increase survival and hence antibody production , J Immunol , 1999 , vol. 162 (pg. 78 - 87 ) 59 , , . Generation and analysis of interleukin-4 deficient mice , Science , 1991 , vol. 254 (pg. 707 - 10 ) 60 , , , et al. IgE class switching is critically dependent upon the nature of the B cell activator, in addition to the presence of IL-4 , J Immunol , 1991 , vol. 147 (pg. 1163 - 70 ) 61
, , , et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells , Proc Natl Acad Sci USA , 1993 , vol. 90 (pg. 3730 - 4 ) 62 , , . Antibody to interleukin 5 prevents blood and tissue eosinophilia but not liver trapping in murine larval toxocariasis , Parasite Immunol , 1993 , vol. 15 (pg. 501 - 8 ) 63 , , , et al. Interleukin-5 mRNA levels in blood and bone marrow mononuclear cells from patients with the idiopathic hypereosinophilic syndrome , Immunology , 1994 , vol. 83 (pg. 308 - 12 ) 64 , , , et al. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia , N Engl J Med , 1999 , vol. 341 (pg. 1112 - 20 ) 65 , , , et al. Modulation of eosinophil chemotaxis by interleukin-5 , Am J Respir Cell Mol Biol , 1992 , vol. 7 (pg. 631 - 6 ) 66 , , , et al. Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge , J Allergy Clin Immunol , 1993 , vol. 92 (pg. 607 - 15 ) 67 , , , et al. IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor potentiate basophil mediator release stimulated by eosinophil granule major basic protein , J Immunol , 1995 , vol. 155 (pg. 2211 - 21 ) 68 , , , et al. Degranulation of human basophils by picomolar concentrations of IL-3, IL-5, or granulocyte-macrophage colony-stimulating factor , J Allergy Clin Immunol , 1998 , vol. 101 (pg. 683 - 90 ) 69 , , , et al. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis , J Leukoc Biol , 1995 , vol. 57 (pg. 353 - 60 ) 70 , , , et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice , J Immunol , 1998 , vol. 160 (pg. 3989 - 96 ) 71 , , , et al. Activation of CD4 + T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma , J Allergy Clin Immunol , 1993 , vol. 92 (pg. 313 - 24 ) 72 , , , et al. Interleukin-4-dependent pulmonary eosinophil infiltration in a murine model of asthma , Am J Respir Cell Mol Biol , 1994 , vol. 10 (pg. 526 - 32 ) 73 , , , et al. Interleukin 9: a candidate gene for asthma , Proc Natl Acad Sci USA , 1997 , vol. 94 (pg. 13175 - 80 ) 74 , , , et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families , J Med Genet , 1998 , vol. 35 (pg. 502 - 4 ) 75 , , , et al. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness , J Exp Med , 1998 , vol. 188 (pg. 1307 - 20 ) 76 , , , et al. Effect of inhaled interleukin-4 on airway hyperreactivity in asthmatics , Am J Respir Crit Care Med , 1998 , vol. 157 (pg. 1818 - 21 ) 77 , , , et al. Effect of inhaled interleukin-5 on number and activity of eosinophils in circulation from asthmatics , Clin Immunol , 1999 , vol. 91 (pg. 163 - 9 ) 78 , , , et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells , J Immunol , 1999 , vol. 162 (pg. 2477 - 87 ) 79 , , . Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor , J Immunol , 1988 , vol. 141 (pg. 2635 - 42 ) 80 , . Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th2 murine helper T lymphocyte clones , J Immunol , 1988 , vol. 140 (pg. 4245 - 52 ) 81 , , , et al. In vitro maturation of human neonatal CD4 T lymphocytes. II. Cytokines present at priming modulate the development of lymphokine production , J Immunol , 1994 , vol. 152 (pg. 4775 - 82 ) 82
, , , et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells , J Exp Med , 1993 , vol. 178 (pg. 1041 - 8 ) 83 , . IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages , J Immunol , 1997 , vol. 159 (pg. 5474 - 82 ) 84 , , , et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1 , Blood , 1999 , vol. 93 (pg. 1456 - 63 ) 85 , , . Interleukin-10 gene knock-out mice: a model of chronic inflammation , Clin Immunol Immunopathol , 1995 , vol. 76 (pg. S174 - 8 ) 86 , , , et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th2 cells , J Immunol , 1991 , vol. 146 (pg. 3444 - 51 ) 87 , , , et al. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes: evidence for an autocrine role of tumor necrosis factor and IL-1 β in mediating the production of IL-8 triggered by lipopolysaccharide , J Exp Med , 1993 , vol. 178 (pg. 2207 - 11 ) 88 , , . Interleukin-10 inhibits neutrophil phagocytic and bactericidal activity , Fems Immunol Med Microbiol , 1996 , vol. 15 (pg. 181 - 7 ) 89 , , , et al. Neutralization of IL-10 up-regulates nitric oxide production and protects susceptible mice from challenge with Candida albicans , J Immunol , 1994 , vol. 152 (pg. 3514 - 21 ) 90 , , , et al. Suppression of superoxide anion production by interleukin-10 is accompanied by a downregulation of the genes for subunit proteins of NADPH oxidase , Exp Hematol , 1996 , vol. 24 (pg. 151 - 7 ) 91 , , , et al. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity , J Immunol , 1992 , vol. 148 (pg. 3578 - 82 ) 92 , , , et al. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans , Eur J Immunol , 1993 , vol. 23 (pg. 1034 - 8 ) 93 , , , et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression , J Exp Med , 1991 , vol. 174 (pg. 915 - 24 ) 94 , , , et al. Inhibition of Langerhans cell antigen-presenting function by IL-10: a role for IL-10 in induction of tolerance , J Immunol , 1993 , vol. 151 (pg. 2390 - 8 ) 95 , , , et al. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4 + T cells , J Exp Med , 1996 , vol. 184 (pg. 19 - 29 ) 96 , , , et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes: comparison with IL-4 and modulation by IFN-gamma or IL-10 , J Immunol , 1993 , vol. 151 (pg. 6370 - 81 ) 97 , , . IL-4 suppression of in vivo T cell activation and antibody production , J Immunol , 2000 , vol. 164 (pg. 1734 - 40 ) 98 , , , et al. Heterogeneity of helper/inducer T lymphocytes. I. Lymphokine production and lymphokine responsiveness , J Exp Med , 1987 , vol. 166 (pg. 1774 - 87 ) 99 , , , et al. Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation , Proc Natl Acad Sci USA , 1986 , vol. 83 (pg. 9689 - 93 ) 100 , , , et al. Role of interleukin 1 in the activation of T lymphocytes , Proc Natl Acad Sci USA , 1988 , vol. 85 (pg. 9699 - 703 ) 101 , , , et al. Heterogeneity of helper/inducer T lymphocytes. III. Responses of IL-2- and IL-4-producing (Th2 and Th2) clones to antigens presented by different accessory cells , J Immunol , 1990 , vol. 145 (pg. 2803 - 8 ) 102 , . Induction of Th2 and Th2 CD4 + T cell responses: the alternative approaches , Annu Rev Immunol , 1997 , vol. 15 (pg. 297 - 322 ) 103 , , , et al. Interleukin 12 acts directly on CD4 + T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming , Proc Natl Acad Sci USA , 1993 , vol. 90 (pg. 10188 - 92 ) 104 , , , et al. Development of TH1 CD4 + T cells through IL-12 produced by Listeria -induced macrophages , Science , 1993 , vol. 260 (pg. 547 - 9 ) 105 , , , et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th2)-specific immune responses and inhibits the development of IL-4-producing Th cells , J Exp Med , 1993 , vol. 177 (pg. 1199 - 204 ) 106 , , , et al. IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells , J Immunol , 1993 , vol. 151 (pg. 1938 - 49 ) 107 , , , et al. Characterization of T helper 1 and 2 cell subsets in normal mice. Helper T cells responsible for IL-4 and IL-5 production are present as precursors that require priming before they develop into lymphokine-secreting cells , J Immunol , 1988 , vol. 141 (pg. 3445 - 55 ) 108 , . Regulation and development of cytochrome c-specific IL-4-producing T cells , J Immunol , 1990 , vol. 145 (pg. 1046 - 52 ) 109 , , , et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses , Nature , 1993 , vol. 362 (pg. 245 - 8 ) 110 , , , et al. Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4 + T cells, analyzed at the single-cell level , J Exp Med , 1996 , vol. 184 (pg. 473 - 83 ) 111 , , , et al. Polarization of IL-4- and IFN-gamma-producing CD4 + T cells following activation of naive CD4 + T cells , J Immunol , 1997 , vol. 158 (pg. 1085 - 94 ) 112 , , , et al. The activated type 1-polarized CD8( + ) T cell population isolated from an effector site contains cells with flexible cytokine profiles , J Exp Med , 1999 , vol. 190 (pg. 1081 - 92 ) 113 , , , et al. Stability of Th2 and Th2 populations , Int Immunol , 1995 , vol. 7 (pg. 869 - 75 ) 114 , , , et al. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation , J Exp Med , 1996 , vol. 183 (pg. 901 - 13 ) 115 , . Induction of a Th2 population from a polarized Leishmania -specific Th2 population by in vitro culture with IL-4 , J Immunol , 1995 , vol. 154 (pg. 3779 - 87 ) 116 , , , et al. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma , Clin Exp Allergy , 2000 , vol. 30 (pg. 341 - 7 ) 117 , , , et al. Coexistence of antigen-specific TH1 and TH2 cells in genetically susceptible BALB/c mice infected with Leishmania major , Immunobiology , 1989 , vol. 179 (pg. 412 - 21 ) 118 , , , et al. Single cell analysis of cytokine gene coexpression during CD4 + T-cell phenotype development , Proc Natl Acad Sci USA , 1995 , vol. 92 (pg. 7565 - 9 ) 119 , , . Novel diversity in Th2, Th2 type differentiation of hemagglutinin-specific T cell clones elicited by natural influenza virus infection in three major haplotypes (H-2b,d,k) , J Immunol , 1998 , vol. 161 (pg. 1094 - 103 ) 120 , . The Th2-Th2 hypothesis of HIV infection: new insights , Immunol Today , 1994 , vol. 15 (pg. 575 - 81 ) 121 , , , et al. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function , J Exp Med , 1990 , vol. 171 (pg. 979 - 96 ) 122 , , , et al. Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia: a clinical research center study , J Clin Endocrinol Metab , 1996 , vol. 81 (pg. 3604 - 6 ) 123 . Glucocorticoids induce a Th2 response in vitro , Dev Immunol , 1998 , vol. 6 (pg. 233 - 43 ) 124 . Differential inhibitory effects of interleukin-10, interleukin-4, and dexamethasone on staphylococcal enterotoxin-induced cytokine production and T cell activation , J Leukoc Biol , 1995 , vol. 57 (pg. 450 - 4 ) 125 , . Effects of a corticosteroid, budesonide, on production of bioactive IL-12 by human monocytes , Cytokine , 1998 , vol. 10 (pg. 786 - 9 ) 126 , , , et al. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential , J Immunol , 1998 , vol. 161 (pg. 5245 - 51 ) 127 , , , et al. Inhibition of Th2 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes , J Immunol , 2000 , vol. 164 (pg. 1768 - 74 ) 128 , , , et al. Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription , J Clin Invest , 1991 , vol. 87 (pg. 1739 - 47 ) 129 , . T cell receptor-independent immunosuppression induced by dexamethasone in murine T helper cells , J Clin Invest , 1992 , vol. 89 (pg. 556 - 60 ) 130 , , , et al. Programmed T lymphocyte death: cell activation- and steroid-induced pathways are mutually antagonistic , J Immunol , 1990 , vol. 145 (pg. 4037 - 45 ) 131 , . Regulation by corticosteroids of Th2 and Th2 cytokine production in human CD4 + effector T cells generated from CD45RO- and CD45RO + subsets , J Immunol , 1995 , vol. 155 (pg. 3322 - 8 ) 132 , , , et al. Adrenal hormone modulation of type 1 and type 2 cytokine production by spleen cells: dexamethasone and dehydroepiandrosterone suppress interleukin-2, interleukin-4, and interferon-gamma production in vitro , Cell Immunol , 1998 , vol. 184 (pg. 58 - 64 ) 133 , , , et al. Resistance to methylprednisolone in cultures of blood mononuclear cells from glucocorticoid-resistant asthmatic patients , Clinical Science , 1984 , vol. 67 (pg. 639 - 45 ) 134 , , , et al. Partial mediation of glucocorticoid antiproliferative effects by lipocortins , J Immunol , 1996 , vol. 157 (pg. 5231 - 9 ) 135 , , , et al. The use of corticosteroids in the treatment of acute asthma , Q J Med , 1975 , vol. 44 (pg. 259 - 73 ) 136 , , , et al. Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function , J Immunol , 1984 , vol. 133 (pg. 2479 - 87 ) 137 . There is a bias against type 1 (inflammatory) cytokine expression and function in pregnancy , J Reprod Immunol , 1996 , vol. 32 (pg. 105 - 10 ) 138 , . A progesterone-dependent immunomodulatory protein alters the Th2/Th2 balance , J Reprod Immunol , 1996 , vol. 31 (pg. 81 - 95 ) 139 , . Estrogen enhances immunoglobulin production by human PBMCs , J Allergy Clin Immunol , 1999 , vol. 103 (pg. 282 - 8 ) 140 , , , et al. IL-10 prevents naturally occurring fetal loss in the CBA × DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau , J Immunol , 1995 , vol. 154 (pg. 4261 - 8 ) 141 , , , et al. Expression and production of interleukin-10 by human trophoblast: relationship to pregnancy immunotolerance , Early Pregnancy , 1997 , vol. 3 (pg. 190 - 8 ) 142 , , , et al. Qualitative and quantitative analysis of T lymphocytes during normal human pregnancy , Am J Reprod Immunol , 1995 , vol. 33 (pg. 381 - 93 ) 143 , , , et al. T helper 1- and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia , Eur J Obstet Gynecol Reprod Biol , 1999 , vol. 86 (pg. 165 - 70 ) 144 , , , et al. Quantitative analysis of peripheral blood Th0, Th2, Th2 and the Th2 : Th2 cell ratio during normal human pregnancy and preeclampsia , Clin Exp Immunol , 1999 , vol. 117 (pg. 550 - 5 ) 145 , , . T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion , JAMA , 1995 , vol. 273 (pg. 1933 - 6 ) 146 , , , et al. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells , J Immunol , 1996 , vol. 156 (pg. 653 - 62 ) 147 , , , et al. Maternal Th2- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions , Cell Immunol , 1999 , vol. 196 (pg. 122 - 30 ) 148 , , . Regulation of murine lymphokine production in vivo. II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells , Eur J Immunol , 1990 , vol. 20 (pg. 793 - 802 ) 149 , , , et al. Dehydroepiandrosterone enhances IL2 production and cytotoxic effector function of human T cells , Clin Immunol Immunopathol , 1991 , vol. 61 (pg. 202 - 11 ) 150 , , , et al. Administration of dehydroepiandrosterone reverses the immune suppression induced by high dose antigen in mice , Immunol Invest , 1995 , vol. 24 (pg. 583 - 93 ) 151 , . Differential Th2 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3 , J Virol , 1994 , vol. 68 (pg. 5126 - 32 ) 152 , , . Lymphocyte blast transformation. I. Demonstration of adrenergic receptors in human peripheral lymphocytes , Cell Immunol , 1970 , vol. 1 (pg. 583 - 95 ) 153 , , , et al. Differential expression of the β2-adrenergic receptor by Th2 and Th2 clones: implications for cytokine production and B cell help , J Immunol , 1997 , vol. 158 (pg. 4200 - 10 ) 154 , , , et al. Modulation of IgE production in the mouse by β2-adrenoceptor agonist , Int Arch Allergy Immunol , 1994 , vol. 105 (pg. 171 - 6 ) 155 , , , et al. Regulation of interleukin-10 production by β-adrenergic agonists , Eur J Immunol , 1996 , vol. 26 (pg. 2601 - 5 ) 156 , , , et al. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications , Proc Assoc Am Physicians , 1996 , vol. 108 (pg. 374 - 81 ) 157 , , , et al. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia , J Clin Invest , 1996 , vol. 97 (pg. 713 - 9 ) 158 , , , et al. Catecholamines trigger IL-10 release in acute systemic stress reaction by direct stimulation of its promoter/enhancer activity in monocytic cells , J Neuroimmunol , 2000 , vol. 105 (pg. 31 - 8 ) 159 , , . Activated T helper 1 and T helper 2 cells differentially express the β2-adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production , J Immunol , 1997 , vol. 159 (pg. 4857 - 67 ) 160 , , . Differential effect of pregnancy or gestagens on humoral and cell-mediated immunity , Clin Exp Immunol , 1977 , vol. 28 (pg. 306 - 14 ) 161 , . Prostaglandin E2 inhibits production of Th2 lymphokines but not of Th2 lymphokines , J Immunol , 1991 , vol. 146 (pg. 108 - 13 ) 162 , , , et al. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production , J Exp Med , 1995 , vol. 181 (pg. 775 - 9 ) 163 , , , et al. Prostaglandin E2 at priming of naive CD4 + T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5 , J Immunol , 1995 , vol. 155 (pg. 4604 - 12 ) 164 , , , et al. Monocyte derived IL 10 and PGE2 are associated with the absence of Th 1 cells and in vitro T cell suppression in lepromatous leprosy , Immunol Lett , 1995 , vol. 48 (pg. 123 - 8 ) 165 , . Influence of alpha-melanocyte stimulating hormone on induction of contact hypersensitivity and tolerance , J Dermatol Sci , 1994 , vol. 8 (pg. 187 - 93 ) 166 , , . Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon , Neuroimmunomodulation , 1994 , vol. 1 (pg. 188 - 94 ) 167 . , Immunity in infective diseases , 1905 Cambridge Cambridge University Press Binnie, FG, trans. Reprint: The sources of science, no. 61. New York: Johnson Reprint Corporation, 1968:166–7 168 . Hepatitis B virus infection , N Engl J Med , 1997 , vol. 337 (pg. 1733 - 45 ) 169 , , , et al. The expression of IL-2, IL-4 and interferon-gamma (IFN-gamma) mRNA using liver biopsies at different phases of acute exacerbation of chronic hepatitis B , Clin Exp Immunol , 1995 , vol. 100 (pg. 446 - 51 ) 170 , , , et al. Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage , J Infect Dis , 1998 , vol. 178 (pg. 247 - 51 ) 171 , , , et al. Hepatitis B core antigen-specific interferon gamma production of peripheral blood mononuclear cells during acute exacerbation of chronic hepatitis B , Scand J Gastroenterol , 1992 , vol. 27 (pg. 727 - 31 ) 172 , , , et al. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies , J Hepatol , 1999 , vol. 31 (pg. 407 - 15 ) 173 , , , et al. Severe exacerbation of chronic active hepatitis B during interferon alpha therapy , Digestion , 1992 , vol. 52 (pg. 61 - 4 ) 174 , , , et al. Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon , Lancet , 1991 , vol. 338 pg. 828 175 , , . Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C , Gastroenterology , 1992 , vol. 102 (pg. 1406 - 8 ) 176 , , . Exacerbation of liver disease during interferon-alpha therapy for chronic hepatitis C , South African Medical Journal , 1994 , vol. 84 pg. 509 177 , , , et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans , J Immunol , 1999 , vol. 162 (pg. 3088 - 95 ) 178 , , , et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B , J Clin Invest , 1998 , vol. 102 (pg. 968 - 75 ) 179 , , , et al. Relative efficiency of microglia, astrocytes, dendritic cells and B cells in naive CD4 + T cell priming and Th2/Th2 cell restimulation , Eur J Immunol , 1999 , vol. 29 (pg. 2705 - 14 ) 180 , . Antigen presentation by hapten-specific B lymphocytes. V. Requirements for activation of antigen-presenting B cells , J Immunol , 1987 , vol. 139 (pg. 2562 - 6 ) 181 , , , et al. B cells solicit their own help from T cells , J Exp Med , 1996 , vol. 183 (pg. 891 - 9 ) 182 , , . Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th2 development , J Immunol , 1999 , vol. 163 (pg. 4284 - 91 ) 183 , , . Regulation of T helper cell cytokine expression: functional dichotomy of antigen-presenting cells , Eur J Immunol , 1993 , vol. 23 (pg. 191 - 9 ) 184 , , . Response of naive antigen-specific CD4 + T cells in vitro: characteristics and antigen-presenting cell requirements , J Exp Med , 1992 , vol. 176 (pg. 1431 - 7 ) 185 , . A quantitative analysis of antigen-presenting cell function: activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation , J Exp Med , 1994 , vol. 180 (pg. 1829 - 40 ) 186 , . Comparison of lung dendritic cells and B cells in stimulating naive antigen-specific T cells , J Immunol , 1999 , vol. 162 (pg. 1310 - 7 ) 187 , , , et al. Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th2 phenotype , Blood , 1997 , vol. 90 (pg. 1920 - 6 ) 188 , , , et al. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells , J Immunol , 1997 , vol. 159 (pg. 28 - 35 ) 189 , , , et al. Induction of Th2 cell differentiation in the primary immune response: dendritic cells isolated from adherent cell culture treated with IL-10 prime naive CD4 + T cells to secrete IL-4 , Int Immunol , 1998 , vol. 10 (pg. 1017 - 26 ) 190 , . The concept of type 1 and type 2 antigen-presenting cells , Immunol Lett , 1999 , vol. 69 (pg. 5 - 6 ) 191 , , . CD28/B7 system of T cell costimulation , Annu Rev Immunol , 1996 , vol. 14 (pg. 233 - 58 ) 192 , , , et al. Strength of TCR signal determines the costimulatory requirements for Th2 and Th2 CD4 + T cell differentiation , J Immunol , 1997 , vol. 159 (pg. 5956 - 63 ) 193 , , , et al. The interplay between the duration of TCR and cytokine signaling determines T cell polarization , Eur J Immunol , 1999 , vol. 29 (pg. 4092 - 101 ) 194 , , . Instruction for cytokine expression in T helper lymphocytes in relation to proliferation and cell cycle progression , J Exp Med , 1999 , vol. 190 (pg. 1439 - 50 ) 195 , . Peptide dose, affinity, and time of differentiation can contribute to the Th2/Th2 cytokine balance , J Immunol , 1999 , vol. 163 (pg. 1205 - 13 ) 196 . An innate sense of danger , Seminars in Immunology , 1998 , vol. 10 (pg. 399 - 415 ) 197 , , , et al. Regulation of murine macrophage IL-12 production: activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines , J Immunol , 1996 , vol. 156 (pg. 1196 - 206 ) 198 , , , et al. Lipotechoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway , Infect Immun , 1996 , vol. 64 (pg. 1906 - 12 ) 199 . The influence of base sequence on the immunostimulatory properties of DNA , Immunologic Research , 1999 , vol. 19 (pg. 35 - 46 ) 200 , , , et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth , Microbiol Immunol , 1992 , vol. 36 (pg. 983 - 97 ) 201 , , , et al. CpG motifs in bacterial DNA trigger direct B-cell activation , Nature , 1995 , vol. 374 (pg. 546 - 9 ) 202 , , , et al. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12 , Clin Immunol Immunopathol , 1997 , vol. 84 (pg. 185 - 93 ) 203 , , , et al. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge , J Immunol , 1998 , vol. 161 (pg. 2428 - 34 ) 204 , , , et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells , Eur J Immunol , 1998 , vol. 28 (pg. 2045 - 54 )
205 , , , et al. Differential regulation of the IL-12 p40 promoter and of p40 secretion by CpG DNA and lipopolysaccharide , J Immunol , 1999 , vol. 162 (pg. 6770 - 5 ) 206 , , . Immunostimulatory properties of genomic DNA from different bacterial species , Immunobiology , 1999 , vol. 200 (pg. 106 - 19 ) 207 , , , et al. Human polymorphonuclear leukocytes produce IL-12, TNF-α, and the chemokines macrophage-inflammatory protein-1α and -1β in response to Toxoplasma gondii antigens , J Immunol , 1999 , vol. 162 (pg. 7369 - 75 ) 208 , , , et al. Macrophages are a significant source of type 1 cytokines during mycobacterial infection , J Clin Invest , 1999 , vol. 103 (pg. 1023 - 9 ) 209 , , , et al. Human 60-kDa heat-shock protein: a danger signal to the innate immune system , J Immunol , 1999 , vol. 162 (pg. 3212 - 9 ) 210 , . Cytosolic free calcium increases before and oscillates during frustrated phagocytosis in macrophages , J Cell Biol , 1987 , vol. 105 (pg. 2685 - 93 ) 211 , , , et al. Rapid fragmentation and reorganization of Golgi membranes during frustrated phagocytosis of immobile immune complexes by macrophages , Am J Pathol , 1989 , vol. 134 (pg. 15 - 26 ) 212 , , , et al. Polymorphonuclear neutrophils release 35S-labelled proteoglycans into cartilage during frustrated phagocytosis , Eur J Biochem , 1994 , vol. 221 (pg. 871 - 9 ) 213 , . Membrane capacitance changes associated with particle uptake during phagocytosis in macrophages , Biophys J , 1998 , vol. 75 (pg. 2577 - 86 ) 214 , , , et al. An immunoregulatory role for neutrophils in CD4 + T helper subset selection in mice with candidiasis , J Immunol , 1997 , vol. 158 (pg. 2356 - 62 ) 215 , , , et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha , J Exp Med , 1995 , vol. 181 (pg. 1615 - 21 ) 216 , , , et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy , J Clin Invest , 1997 , vol. 99 (pg. 336 - 41 ) 217 . The role of type I interferons in the differentiation and function of Th2 and Th2 cells , Semin Oncol , 1997 , vol. 24 (pg. S9-94 - S9-8 ) 218 , , , et al. Induction of IFN-gamma-producing CD4 + natural killer T cells by Mycobacterium bovis bacillus Calmette Guérin , Eur J Immunol , 1999 , vol. 29 (pg. 650 - 9 ) 219 , , , et al. Direct interaction of STAT4 with the IL-12 receptor , Arch Biochem Biophys , 1999 , vol. 368 (pg. 147 - 55 ) 220 , , , et al. Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes , Proc Natl Acad Sci USA , 1995 , vol. 92 (pg. 7307 - 11 ) 221 , , , et al. An interleukin-4-induced transcription factor: IL-4 Stat , Science , 1994 , vol. 265 (pg. 1701 - 6 ) 222 , , , et al. Cytokine transcriptional events during helper T cell subset differentiation , J Exp Med , 1996 , vol. 184 (pg. 397 - 406 ) 223 , , , et al. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice , Nature , 1996 , vol. 382 (pg. 174 - 7 ) 224 , , , et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells , Nature , 1996 , vol. 382 (pg. 171 - 4 ) 225 , , , et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene , Nature , 1996 , vol. 380 (pg. 630 - 3 ) 226 , , , et al. Essential role of Stat6 in IL-4 signalling , Nature , 1996 , vol. 380 (pg. 627 - 30 ) 227 , , , et al. Transcription factor GATA-3 is differentially expressed in murine Th2 and Th2 cells and controls Th2-specific expression of the interleukin-5 gene , J Biol Chem , 1997 , vol. 272 (pg. 21597 - 603 ) 228 , . The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells , Cell , 1997 , vol. 89 (pg. 587 - 96 ) 229 , , , et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment , Immunity , 2000 , vol. 12 (pg. 27 - 37 ) 230 , , , et al. The Ets transcription factor ERM is Th2-specific and induced by IL-12 through a Stat4-dependent pathway , Proc Natl Acad Sci USA , 1999 , vol. 96 (pg. 3888 - 93 ) 231 , , , et al. A novel transcription factor, T-bet, directs Th2 lineage commitment , Cell , 2000 , vol. 100 (pg. 655 - 69 ) 232 , , . Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand black/white F1 lupus-prone mice and the Leishmania major -susceptible BALB/c strain , J Immunol , 1998 , vol. 161 (pg. 6878 - 84 ) 233 , , , et al. The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor β-2-chain expression on CD4 + T cells, resulting in a state of unresponsiveness to IL-12 , J Immunol , 1998 , vol. 161 (pg. 6156 - 63 ) 234 , , , et al. Murine cutaneous leishmaniasis: resistance correlates with the capacity to generate interferon-gamma in response to Leishmania antigens in vitro , J Immunol , 1986 , vol. 136 (pg. 655 - 61 ) 235 , , , et al. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets , Ann Inst Pasteur Immunol , 1987 , vol. 138 (pg. 744 - 9 ) 236 , , . Leishmania major : analysis of lymphocyte and macrophage cellular phenotypes during infection of susceptible and resistant mice , Exp Parasitol , 1988 , vol. 65 (pg. 258 - 68 ) 237 , , , et al. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens , J Exp Med , 1988 , vol. 168 (pg. 1675 - 84 ) 238 , , , et al. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets , J Exp Med , 1989 , vol. 169 (pg. 59 - 72 ) 239 , , , et al. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4 + lymphocytes in vivo during healing and progressive murine leishmaniasis , Proc Natl Acad Sci USA , 1991 , vol. 88 (pg. 7011 - 5 ) 240 , , , et al. IL-4-deficient Balb/c mice resist infection with Leishmania major , J Exp Med , 1996 , vol. 184 (pg. 1127 - 36 ) 241 , , , et al. Mice with STAT6-targeted gene disruption develop a Th2 response and control cutaneous leishmaniasis , J Immunol , 1998 , vol. 161 (pg. 6180 - 8 ) 242 , , , et al. Leishmania major infection in interleukin-4 and interferon-gamma depleted mice , Parasite Immunol , 1999 , vol. 21 (pg. 423 - 31 ) 243 , , , et al. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines , J Immunol , 1996 , vol. 156 (pg. 644 - 52 ) 244 , , , et al. The role of IL-12 in the maintenance of an established Th2 immune response in experimental leishmaniasis , Eur J Immunol , 1998 , vol. 28 (pg. 2227 - 33 ) 245 , , , et al. Reconstitution of Leishmania immunity in severe combined immunodeficient mice using Th2- and Th2-like cell lines , J Immunol , 1991 , vol. 147 (pg. 1653 - 8 ) 246 , , , et al. IL-12 transiently induces IFN-gamma transcription and protein synthesis in human CD4 + allergen-specific Th2 T cell clones , Int Immunol , 1994 , vol. 6 (pg. 1091 - 6 ) 247 , , , et al. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and pentostam , Proc Natl Acad Sci USA , 1995 , vol. 92 (pg. 3142 - 6 ) 248 , , , et al. Establishment of stable, cell-mediated immunity that makes “susceptible” mice resistant to Leishmania major , Science , 1992 , vol. 257 (pg. 539 - 42 ) 249 , . Parasite dose determines the Th2/Th2 nature of the response to Leishmania major independently of infection route and strain of host or parasite , Eur J Immunol , 1998 , vol. 28 (pg. 4020 - 8 ) 250 , , , et al. Th2 dominance in the immune response to live Salmonella typhimurium requires bacterial invasiveness but not persistence , Int Immunol , 1999 , vol. 11 (pg. 481 - 9 ) 251 , , , et al. Interferon-gamma plays a critical role in intestinal immunity against Salmonella typhimurium infection , Immunology , 2000 , vol. 99 (pg. 464 - 72 ) 252 , , , et al. Th2 pattern of cytokine secretion by splenic cells from pyelonephritic mice after in-vitro stimulation with hsp-65 of Escherichia coli , J Med Microbiol , 1997 , vol. 46 (pg. 139 - 44 ) 253 , , . Long-lived protective immunity to Listeria is conferred by immunization with particulate or soluble listerial antigen preparations coadministered with IL-12 , Cell Immunol , 1998 , vol. 184 (pg. 92 - 104 ) 254 , , , et al. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th2-dominated responses , J Immunol , 1998 , vol. 161 (pg. 4146 - 52 ) 255 , , . Both innate and acquired immunity to Listeria monocytogenes infection are increased in IL-10-deficient mice , J Immunol , 1997 , vol. 158 (pg. 2259 - 67 ) 256 , , , et al. Differential production of interferon-gamma and interleukin-4 in response to Th2- and Th2-stimulating pathogens by gamma delta T cells in vivo , Nature , 1995 , vol. 373 (pg. 255 - 7 ) 257 , , , et al. Chronic Pseudomonas aeruginosa lung infection is more severe in Th2 responding BALB/c mice compared to Th2 responding C3H/HeN mice , APMIS , 1997 , vol. 105 (pg. 838 - 42 ) 258 , , , et al. Vaccination promotes Th2-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia: a new prophylactic principle , Behring Inst Mitt , 1997 , vol. 41 (pg. 269 - 73 ) 259 , , , et al. Involvement of T cells in enhanced resistance to Klebsiella pneumoniae septicemia in mice treated with liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or gamma interferon , Infect Immun , 1998 , vol. 66 (pg. 1962 - 7 ) 260 , , , et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus , Microbiology , 1999 , vol. 145 (pg. 211 - 20 ) 261 , , , et al. Interferon consensus sequence binding protein confers resistance against Yersinia enterocolitica , Infect Immun , 2000 , vol. 68 (pg. 1408 - 17 ) 262 , , , et al. The possible role of interleukin (IL)-12 and interferon-gamma-inducing factor/IL-18 in protection against experimental Mycobacterium leprae infection in mice , Clin Immunol Immunopathol , 1998 , vol. 88 (pg. 226 - 31 ) 263 , , , et al. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice , Infect Immun , 1999 , vol. 67 (pg. 2585 - 9 ) 264 , , , et al. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection , J Immunol , 1993 , vol. 151 (pg. 518 - 25 ) 265 , , , et al. Gamma interferon modifies CD4 + subset expression in murine candidiasis , Infect Immun , 1992 , vol. 60 (pg. 4950 - 2 ) 266 , , , et al. Low-dose streptozotocininduced diabetes in mice. II. Susceptibility to Candida albicans infection correlates with the induction of a biased Th2-like antifungal response , Cell Immunol , 1993 , vol. 150 (pg. 36 - 44 ) 267 , . Interleukin-12 regulation of host defenses against Coccidioides immitis , Infect Immun , 1996 , vol. 64 (pg. 3609 - 13 ) 268 , , , et al. Th2 and Th2 cytokines in mice with invasive aspergillosis , Infect Immun , 1997 , vol. 65 (pg. 564 - 70 ) 269 , , , et al. Interleukin-12 is essential for a protective Th2 response in mice infected with Cryptococcus neoformans , Infect Immun , 1998 , vol. 66 (pg. 4994 - 5000 ) 270 , , , et al. Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen , Infect Immun , 1999 , vol. 67 (pg. 2935 - 40 ) 271 , , , et al. Neutralizing antibody to interleukin 4 induces systemic protection and T helper type 1-associated immunity in murine candidiasis , J Exp Med , 1992 , vol. 176 (pg. 19 - 25 ) 272 , , , et al. CD4 + T-helper-cell responses in mice with low-level Candida albicans infection , Infect Immun , 1996 , vol. 64 (pg. 4907 - 14 ) 273 , , , et al. Induction of protective Th2 responses to Candida albicans by antifungal therapy alone or in combination with an interleukin-4 antagonist , J Infect Dis , 1997 , vol. 176 (pg. 217 - 26 ) 274 , , , et al. Host immune reactivity determines the efficacy of combination immunotherapy and antifungal chemotherapy in candidiasis , J Infect Dis , 2000 , vol. 181 (pg. 686 - 94 ) 275 , . Cellular immune responses to the murine nematode parasite Trichuris muris . I. Differential cytokine production during acute or chronic infection , Immunology , 1991 , vol. 72 (pg. 508 - 13 ) 276 , , . Host protective immunity to Trichinella spiralis in mice: activation of Th cell subsets and lymphokine secretion in mice expressing different response phenotypes , Immunology , 1991 , vol. 74 (pg. 329 - 32 ) 277 , , . Cellular immune responses to the murine nematode parasite Trichuris muris . II. Differential induction of Th-cell subsets in resistant versus susceptible mice , Immunology , 1992 , vol. 75 (pg. 232 - 7 ) 278 , , . Correlations between worm burden and markers of Th2 and Th2 cell subset induction in an inbred strain of mouse infected with Trichuris muris , Parasite Immunol , 1993 , vol. 15 (pg. 595 - 600 ) 279 , , , et al. Functional correlations between mucosal mast cell activity and immunity to Trichinella spiralis in high and low responder mice , Parasite Immunol , 1990 , vol. 12 (pg. 675 - 85 ) 280 , , , et al. The in vivo role of stem cell factor (c-kit ligand) on mastocytosis and host protective immunity to the intestinal nematode Trichinella spiralis in mice , Parasite Immunol , 1993 , vol. 15 (pg. 55 - 9 ) 281 , , , et al. Stat6 signaling promotes protective immunity against Trichinella spiralis through a mast cell- and T cell-dependent mechanism , J Immunol , 2000 , vol. 164 (pg. 2046 - 52 ) 282 , , , et al. Interleukin-9 enhances resistance to the intestinal nematode Trichuris muris , Infect Immun , 1998 , vol. 66 (pg. 3832 - 40 ) 283 , , , et al. Interleukin-9 is involved in host protective immunity to intestinal nematode infection , Eur J Immunol , 1997 , vol. 27 (pg. 2536 - 40 ) 284 , , , et al. Anti-IL-9 vaccination prevents worm expulsion and blood eosinophilia in Trichuris muris -infected mice , Proc Natl Acad Sci USA , 2000 , vol. 97 (pg. 767 - 72 ) 285 , , , et al. Cytokine-mediated regulation of chronic intestinal helminth infection , J Exp Med , 1994 , vol. 179 (pg. 347 - 51 ) 286 , , , et al. Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites , J Exp Med , 1994 , vol. 179 (pg. 1563 - 72 ) 287 , , , et al. Interleukin-12 promotes a chronic intestinal nematode infection , Eur J Immunol , 1997 , vol. 27 (pg. 866 - 70 ) 288 , . Regulation of immunity to parasites by T cells and T cell-derived cytokines , Annu Rev Immunol , 1992 , vol. 10 (pg. 385 - 409 ) 289 , , . Evidence for differential induction of helper T cell subsets during Trichinella spiralis infection , J Immunol , 1989 , vol. 143 (pg. 4232 - 7 ) 290 , , , et al. Fc epsilonRI-deficient mice infected with Schistosoma mansoni mount normal Th2-type responses while displaying enhanced liver pathology , J Immunol , 1997 , vol. 159 (pg. 1868 - 75 ) 291 , , , et al. IgE antibody and resistance to infection. II. Effect of IgE suppression on the early and late skin reaction and resistance of rats to Schistosoma mansoni infection , Eur J Immunol , 1986 , vol. 16 (pg. 589 - 95 ) 292 , , . Schistosoma mansoni: protective immunity in IL-4-deficient mice , Exp Parasitol , 1996 , vol. 84 (pg. 245 - 52 ) 293 , . Interrelationship of eosinophilia and IgE antibody production to larval ES antigen in Toxocara canis infected mice , Parasite Immunol , 1984 , vol. 6 (pg. 409 - 20 ) 294 , , . Antibody responses and protective immunity in rats receiving repeated inoculations of Strongyloides ratti , J Parasitol , 1991 , vol. 77 (pg. 737 - 41 ) 295 , , , et al. Temporal changes in Trichuris trichiura infection intensity and serum isotype responses in children , Parasitology , 1994 , vol. 109 (pg. 197 - 200 ) 296 , , , et al. Nippostrongylus brasiliensis: cytokine responses and nematode expulsion in normal and IL-4-deficient mice , Exp Parasitol , 1996 , vol. 84 (pg. 65 - 73 ) 297 , , . A critical role for IL-13 in resistance to intestinal nematode infection , J Immunol , 1998 , vol. 160 (pg. 3453 - 61 ) 298 , , , et al. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor , J Biol Chem , 1995 , vol. 270 (pg. 13869 - 78 ) 299 , , , et al. Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types , J Biol Chem , 1995 , vol. 270 (pg. 3512 - 7 ) 300 , , , et al. Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor , Int Immunol , 1996 , vol. 8 (pg. 1915 - 25 ) 301 , , , et al. IL-13, IL-4Rα, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite Nippostrongylus brasiliensis , Immunity , 1998 , vol. 8 (pg. 255 - 64 ) 302 , , , et al. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses , J Exp Med , 1999 , vol. 189 (pg. 1565 - 72 ) 303 , , , et al. Tumor necrosis factor alpha is a critical component of interleukin 13-mediated protective T helper cell type 2 responses during helminth infection , J Exp Med , 1999 , vol. 190 (pg. 953 - 62 ) 304 , , , et al. Cytokine patterns in the pathogenesis of human leishmaniasis , J Clin Invest , 1993 , vol. 91 (pg. 1390 - 5 ) 305 , , , et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections , J Clin Invest , 1993 , vol. 92 (pg. 324 - 9 ) 306 , , , et al. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th2 cells in humans with naturally acquired immunity to L. major , Fems Immunol Med Microbiol , 1998 , vol. 20 (pg. 209 - 18 ) 307 , , , et al. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis , J Immunol , 1994 , vol. 152 (pg. 5949 - 56 ) 308 , , . Haemophilus influenzae and Streptococcus pyogenes group A challenge induce a Th2 type of cytokine response in cells obtained from tonsillar hypertrophy and recurrent tonsillitis , ORL J Otorhinolaryngol Rel Spec , 1998 , vol. 60 (pg. 35 - 41 ) 309 , , , et al. Gamma interferon and interleukin 2, but not interleukin 4, are detectable in gamma/delta T-cell cultures after activation with bacteria , Infect Immun , 1992 , vol. 60 (pg. 1229 - 31 ) 310 , , , et al. Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells , Infect Immun , 1998 , vol. 66 (pg. 6058 - 62 ) 311 , , , et al. Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci , Infect Immun , 2000 , vol. 68 (pg. 320 - 7 ) 312 , , , et al. Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection , J Clin Invest , 1998 , vol. 102 (pg. 2035 - 40 ) 313 , , , et al. Severe mycobacterial and salmonella infections in interleukin-12 receptor-deficient patients , Science , 1998 , vol. 280 (pg. 1435 - 8 ) 314 , , , et al. Interleukin 12 deficiency associated with recurrent infections , Proc Natl Acad Sci USA , 1998 , vol. 95 (pg. 13125 - 9 ) 315 , , , et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNγR1) deficiency: mutational analysis and evaluation of therapeutic options , Exp Hematol , 1999 , vol. 27 (pg. 1368 - 74 ) 316 , . Cytokine patterns at the site of mycobacterial infection , Immunobiology , 1994 , vol. 191 (pg. 378 - 87 ) 317 , , , et al. Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae , Immunology , 1995 , vol. 86 (pg. 97 - 103 ) 318 , , . The spectrum of human tuberculosis , Clin Exp Immunol , 1977 , vol. 27 (pg. 230 - 7 ) 319 , , , et al. Relationships between titers of antibodies immunoreacting against glycolipid antigens from Mycobacterium leprae and M. tuberculosis , the Mitsuda and Mantoux reactions, and bacteriological loads: implications in the pathogenesis, epidemiology and serodiagnosis of leprosy and tuberculosis , Int J Lepr Other Mycobact Dis , 1992 , vol. 60 (pg. 208 - 24 ) 320 , , , et al. Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls , Infect Immun , 1994 , vol. 62 (pg. 5673 - 8 ) 321 , , , et al. Th2/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens , Immunology , 1994 , vol. 81 (pg. 171 - 6 ) 322 , , . Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis , J Infect Dis , 2000 , vol. 181 (pg. 385 - 9 ) 323 , . Defective monocyte costimulation for IFN-gamma production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation , J Immunol , 1996 , vol. 157 (pg. 411 - 6 ) 324 , , , et al. Infections in IFNGR-1-deficient children , J Interferon Cytokine Res , 1997 , vol. 17 (pg. 583 - 7 ) 325 , , , et al. Fatal disseminated Mycobacterium smegmatis infection in a child with inherited interferon gamma receptor deficiency , Clin Infect Dis , 1997 , vol. 24 (pg. 982 - 4 ) 326 , , , et al. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency , J Infect Dis , 1998 , vol. 178 (pg. 1095 - 104 ) 327 , , , et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency , Science , 1998 , vol. 280 (pg. 1432 - 5 ) 328 , , , et al. Sequential production of Th2 and Th2 cytokines in response to live bacillus Calmette-Guérin , Immunology , 1995 , vol. 86 (pg. 512 - 8 ) 329 , , , et al. Cytokine gene expression in human peripheral blood mononuclear cells stimulated by mannoprotein constituents from Candida albicans , Infect Immun , 1993 , vol. 61 (pg. 4105 - 11 ) 330 , , , et al. Chronic mucocutaneous candidiasis. I. Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-gamma) production , Clin Exp Immunol , 1996 , vol. 105 (pg. 205 - 12 ) 331 , , , et al. Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidia , FEMS Immunol Med Microbiol , 1997 , vol. 19 (pg. 169 - 80 ) 332 , , , et al. Long-term itraconazole prophylaxis against aspergillus infections in thirty-two patients with chronic granulomatous disease , J Pediatr , 1994 , vol. 125 (pg. 998 - 1003 ) 333 , , , et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae , J Infect Dis , 1991 , vol. 163 (pg. 849 - 52 ) 334 A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease The International Chronic Granulomatous Disease Cooperative Study Group , N Engl J Med , 1991 , vol. 324 (pg. 509 - 16 ) 335 , , , et al. Th2 and Th2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients , AIDS , 1994 , vol. 8 (pg. 757 - 62 ) 336 , , , et al. Human immunodeficiency virus (HIV) phenotype and interleukin-2/interleukin-10 ratio are associated markers of protection and progression in HIV infection , Blood , 1996 , vol. 88 (pg. 574 - 9 ) 337 , , . Endogenous interleukin-2 serum levels in children infected with human immunodeficiency virus , Clin Infect Dis , 1997 , vol. 25 (pg. 1233 - 6 ) 338 , , , et al. Dysregulated production of interleukin-10 (IL-10) and IL-12 by peripheral blood lymphocytes from human immunodeficiency virus-infected individuals is associated with altered proliferative responses to recall antigens , Clin Diagn Lab Immunol , 1995 , vol. 2 (pg. 712 - 8 ) 339 , , , et al. HIV infection suppresses type 1 lymphokine and IL-12 responses to Toxoplasma gondii but fails to inhibit the synthesis of other parasite-induced monokines , J Immunol , 1995 , vol. 155 (pg. 1565 - 74 ) 340 , , , et al. The interleukin-12-mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals , Blood , 1999 , vol. 94 (pg. 1003 - 11 ) 341 , , , et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro , Science , 1993 , vol. 262 (pg. 1721 - 4 ) 342 , , , et al. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy , AIDS Res Hum Retroviruses , 1999 , vol. 15 (pg. 1499 - 508 ) 343 , , , et al. Restoration of normal interleukin-2 production by CD4 + T cells of human immunodeficiency virus-infected patients after 9 months of highly active antiretroviral therapy , J Infect Dis , 1999 , vol. 180 (pg. 1057 - 63 ) 344 , , , et al. Current laboratory assays and in vitro intracellular Th2 and Th2 cytokine synthesis in monitoring antiretroviral therapy of pediatric HIV infection , FEMS Immunol Med Microbiol , 2000 , vol. 27 (pg. 67 - 71 ) 345 , , , et al. CCR5 is characteristic of Th2 lymphocytes , Nature , 1998 , vol. 391 (pg. 344 - 5 ) 346 , , , et al. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes , J Exp Med , 1998 , vol. 187 (pg. 875 - 83 ) 347 , , , et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions , J Clin Invest , 1998 , vol. 101 (pg. 746 - 54 ) 348 , , , et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection , Science , 1993 , vol. 261 (pg. 1179 - 81 ) 349 , , , et al. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor , Science , 1996 , vol. 272 (pg. 872 - 7 ) 350 , , , et al. Circadian variations in plasma levels of hypophyseal, adrenocortical and testicular hormones in men infected with human immunodeficiency virus , J Clin Endocrinol Metab , 1990 , vol. 70 (pg. 572 - 7 ) 351 , , , et al. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting , J Clin Endocrinol Metab , 1996 , vol. 81 (pg. 4051 - 8 ) 352 , , , et al. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting [published erratum in: J Clin Endocrinol Metab 1997; 82(10):3360] , J Clin Endocrinol Metab , 1997 , vol. 82 (pg. 1332 - 7 ) 353 , , , et al. Relationship between sex steroid hormone levels and CD4 lymphocytes in HIV infected men , Exp Clin Endocrinol Diabetes , 1996 , vol. 104 (pg. 130 - 6 ) 354 , , , et al. Serum cortisol and DHEA concentrations during HIV infection , Psychoneuroendocrinology , 1997 , vol. 22 Suppl 1 (pg. S11 - 8 ) 355 , , , et al. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200–499 , J Infect Dis , 1991 , vol. 164 (pg. 864 - 8 ) 356 , , , et al. Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men , J Infect Dis , 1992 , vol. 165 (pg. 413 - 8 ) 357 , , , et al. Adrenal function in HIV infected patients , Acta Endocrinol , 1989 , vol. 121 (pg. 633 - 7 ) 358 , , , et al. A possible role for the cortisol/anticortisols imbalance in the progression of human immunodeficiency virus , Psychoneuroendocrinology , 1997 , vol. 22 Suppl 1 (pg. S27 - 31 ) 359 , , , et al. Immunologic characterization of children vertically infected with human immunodeficiency virus, with slow or rapid disease progression , J Pediatr , 1995 , vol. 126 (pg. 368 - 74 ) 360 , , , et al. Elevation of IgE in HIV-infected children and its correlation with the progression of disease , J Allergy Clin Immunol , 1995 , vol. 95 (pg. 627 - 32 ) 361 , , , et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus , N Engl J Med , 1996 , vol. 335 (pg. 1350 - 6 ) 362 , , , et al. Coadministration of zidovudine and interleukin-2 increases absolute CD4 cells in subjects with Walter Reed stage 2 human immunodeficiency virus infection: results of ACTG protocol 042 , J Infect Dis , 1998 , vol. 178 (pg. 1170 - 3 ) 363 , , , et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group , J Infect Dis , 1998 , vol. 178 (pg. 992 - 9 ) 364 , , , et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 Study Group , Lancet , 1999 , vol. 353 (pg. 1923 - 9 ) 365 , , , et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons , J Infect Dis , 1997 , vol. 175 (pg. 781 - 9 ) 366 , , , et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV + subjects , J Clin Invest , 1997 , vol. 100 (pg. 2737 - 43 ) 367 , , , et al. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies , J Clin Invest , 1998 , vol. 101 (pg. 1373 - 8 ) 368 , , , et al. Glucocorticoids and the immune function in the human immunodeficiency virus infection: a study in hypercortisolemic and cortisol-resistant patients , J Clin Endocrinol Metab , 1997 , vol. 82 (pg. 3260 - 3 ) 369 , , , et al. Glucocorticoids and interferon-alpha in the acquired immunodeficiency syndrome , J Clin Endocrinol Metab , 1996 , vol. 81 (pg. 2601 - 6 ) 370 , . Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation , Proc Natl Acad Sci USA , 1998 , vol. 95 (pg. 9488 - 93 ) 371 , , , et al. A double-blind, placebo-controlled study of Mycobacterium -specific human immune responses induced by intradermal bacille Calmette-Guérin vaccination , J Lab Clin Med , 1999 , vol. 134 (pg. 244 - 52 ) 372 , , , et al. Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guérin , J Immunol , 1997 , vol. 158 (pg. 1949 - 55 ) 373 , , . Nonviable bacterial antigens administered with IL-12 generate antigen-specific T cell responses and protective immunity against Listeria monocytogenes , J Immunol , 1995 , vol. 155 (pg. 4817 - 28 ) 374 , , . Induction of Th2 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant , J Immunol , 1996 , vol. 156 (pg. 4739 - 45 ) 375 , , , et al. Development of Th2 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes , J Immunol , 1998 , vol. 160 (pg. 1320 - 9 ) 376 , , , et al. Activity and safety of DNA plasmids encoding IL-4 and IFN gamma , Gene Therapy , 1999 , vol. 6 (pg. 237 - 44 ) 377 , , , et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens , J Immunol , 1997 , vol. 159 (pg. 3638 - 47 ) 378 , , , et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens , Eur J Immunol , 1998 , vol. 28 (pg. 1089 - 103 ) 379 , , . Contribution of CpG motifs to the immunogenicity of DNA vaccines , J Immunol , 1997 , vol. 158 (pg. 3635 - 9 ) 380 , , , et al. In vivo modulation of vaccine-induced immune responses toward a Th2 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model , J Virol , 1999 , vol. 73 (pg. 501 - 9 ) 381 , , , et al. Th2-biased immune responses induced by DNA-based immunizations are mediated via action on professional antigen-presenting cells to up-regulate IL-12 production , Clin Exp Immunol , 2000 , vol. 119 (pg. 130 - 9 ) 382 , , , et al. T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice , J Immunol , 1990 , vol. 144 (pg. 4333 - 9 ) 383 , , , et al. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo , J Virol , 1996 , vol. 70 (pg. 7103 - 7 ) 384 , , , et al. Protection against respiratory syncytial virus infection by DNA immunization , J Exp Med , 1998 , vol. 188 (pg. 681 - 8 ) 385 , , , et al. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis , Infect Immun , 1999 , vol. 67 (pg. 826 - 33 ) 386 , , , et al. Use of recombinant viruses to deliver cytokines influencing the course of experimental bacterial infection , Immunol Cell Biol , 1999 , vol. 77 (pg. 324 - 30 ) 387 . Hormonal profiles in children with progressively worsening nutritional status , Hum Nutr Clin Nutr , 1982 , vol. 36C (pg. 81 - 6 ) 388 , . Concentration patterns of plasma dehydroepiandrosterone, delta 5-androstenediol and their sulphates, testosterone and cortisol in normal healthy women and in women with anorexia nervosa , Acta Endocrinol , 1985 , vol. 108 (pg. 255 - 60 ) 389 , , . Weight loss causes neuroendocrine disturbances: experimental study in healthy starving subjects , Psychiatry Res , 1986 , vol. 17 (pg. 61 - 72 ) 390 , , , et al. Decreased CD4 + lymphocyte activation and increased interleukin-4 production in peripheral blood of rheumatoid arthritis patients after acute starvation , Clin Rheumatol , 1999 , vol. 18 (pg. 394 - 401 ) 391 , , . Increased urinary excretion of cortisol and catecholami-NES in malnourished cancer patients , Ann Surg , 1988 , vol. 208 (pg. 645 - 50 ) 392 , , , et al. Analysis of Th2 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients , Cancer Immunol Immunother , 1999 , vol. 48 (pg. 435 - 42 ) 393 , , , et al. Dysregulation of immune response following neurosurgical operations , Acta Anaesthesiol Scand , 2000 , vol. 44 (pg. 82 - 7 ) 394 , . Plasma norepinephrine in congestive heart failure , Am J Cardiol , 1978 , vol. 41 (pg. 233 - 43 ) 395 , , , et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure , N Engl J Med , 1984 , vol. 311 (pg. 819 - 23 ) 396 , , , et al. Free and conjugated plasma catecholamines in patients with congestive heart failure , J Lab Clin Med , 1984 , vol. 103 (pg. 393 - 8 ) 397 , , , et al. The nutritional status in advanced emphysema associated with chronic bronchitis. A study of amino acid and catecholamine levels , Am Rev Resp Dis , 1990 , vol. 141 (pg. 902 - 8 ) 398 , , , et al. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis , J Hepatol , 1988 , vol. 6 (pg. 350 - 8 ) 399 , , , et al. Effect of nutritional therapy on polyamine metabolism in severely traumatized patients , Nutrition , 1991 , vol. 7 (pg. 39 - 44 ) 400 , , , et al. The catecholamine response to multisystem trauma , Arch Surg , 1992 , vol. 127 (pg. 899 - 903 ) 401 , , , et al. Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery , Am J Surg , 1999 , vol. 177 (pg. 55 - 60 ) 402 , , , et al. Surgical stress induces a shift in the type-1/type-2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma , Surgery , 1996 , vol. 119 (pg. 316 - 25 ) 403 , , , et al. Modulating effects of the feeding route on stress response and endotoxin translocation in severely stressed patients receiving thoracic esophagectomy , Nutrition , 2000 , vol. 16 (pg. 355 - 60 ) 404 , , , et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone , N Engl J Med , 1987 , vol. 316 (pg. 889 - 97 ) 405 , , , et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production , Blood , 1997 , vol. 90 (pg. 2541 - 8 ) 406 , , , et al. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis , Novartis Foundation Symposium , 1998 , vol. 217 (pg. 99 - 106 ) [discussion, 106–11] 407 , , , et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C , Hepatology , 1999 , vol. 29 (pg. 1280 - 7 ) 408 , , , et al. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B , J Hepatol , 2000 , vol. 32 (pg. 317 - 24 ) 409 , , , et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses , J Immunol , 1995 , vol. 154 (pg. 5492 - 9 ) 410 , , , et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans , J Clin Immunol , 1996 , vol. 16 (pg. 291 - 303 ) 411 , , , et al. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10 , Pharmaceutical Research , 1998 , vol. 15 (pg. 1895 - 901 ) 412 , , , et al. Interleukin 10 treatment of psoriasis: clinical results of a phase 2 trial , Arch Dermatol , 1999 , vol. 135 (pg. 187 - 92 ) 413 , , , et al. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy , Transplantation , 1997 , vol. 64 (pg. 999 - 1006 ) 414 , , . Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group , Gastroenterology , 1997 , vol. 113 (pg. 383 - 9 ) 415 , , , et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial , Am J Respir Crit Care Med , 1999 , vol. 160 (pg. 1816 - 23 ) 416 , , , et al. Liposomes containing interferon-gamma as adjuvant in tumor cell vaccines , Pharmaceutical Research , 2000 , vol. 17 (pg. 42 - 8 ) 417 , , , et al. Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes , J Immunother , 2000 , vol. 23 (pg. 131 - 45 ) Author notesFinancial support: National Institutes of Health / National Insititute of Allergy and Infectious Diseases (grants RO1 AI19990 and PO1 AI37194), University of Alabama Clinical Trials of Antifungal Therapies, and Bristol Meyers Squibb Award. © 2001 by the Infectious Diseases Society of America © 2001 by the Infectious Diseases Society of America
Topic:
I agree to the terms and conditions. You must accept the terms and conditions. Submit a comment Name Affiliations Comment title Comment You have entered an invalid code Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email. CitationsViewsAltmetricEmail alertsRelated articles in PubMedCiting articles via
More from Oxford Academic What is a Type 1 immune response?Type I hypersensitivity is the most common type of hypersensitivity reaction. It is an allergic reaction provoked by re-exposure to a specific type of antigen, referred to as an allergen. Unlike the normal immune response, the type I hypersensitivity response is characterized by the secretion of IgE by plasma cells.
What are the 3 immune responses?Humans have three types of immunity — innate, adaptive, and passive: Innate immunity: Everyone is born with innate (or natural) immunity, a type of general protection.
What is the 1st 2nd and 3rd line of defense immune system?The immune system's three lines of defense include physical and chemical barriers, non-specific innate responses, and specific adaptive responses.
What is a Type 2 immune response?The T helper type 2 (Th2) immune response, characterized by the production of interleukin-4 (IL-4), IL-5 and IL-13, is a critical immune response against helminths invading cutaneous or mucosal sites. It also plays a critical role in the pathophysiology of allergic diseases such as asthma and allergic diarrhoea.
|
